Vireo Growth（VREO）株式概要ヴィレオ・グロース社は、メリーランド州、ミネソタ州、ニューヨーク州で医療用および成人用大麻製品の栽培、製造、加工、販売を行う大麻会社として営業している。 詳細VREO ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長2/6過去の実績0/6財務の健全性3/6配当金0/6報酬当社が推定した公正価値より89.6%で取引されている 収益は年間35.11%増加すると予測されています リスク分析過去5年間で収益は年間16%減少しました。 過去1年間で株主の希薄化は大幅に進んだ すべてのリスクチェックを見るVREO Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW487,572 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG487,572 investors already sharing narrativesYour Fair ValueCA$Current PriceCA$13.7352.4% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-82m2b2016201920222025202620282031Revenue US$1.6bEarnings US$230.9mAdvancedSet Fair ValueView all narrativesVireo Growth Inc. 競合他社Cipher PharmaceuticalsSymbol: TSX:CPHMarket cap: CA$416.3mKnight TherapeuticsSymbol: TSX:GUDMarket cap: CA$951.4mVerano HoldingsSymbol: NEOE:VRNOMarket cap: CA$604.9mCanopy GrowthSymbol: TSX:WEEDMarket cap: CA$553.0m価格と性能株価の高値、安値、推移の概要Vireo Growth過去の株価現在の株価CA$13.7352週高値CA$32.4052週安値CA$12.57ベータ0.0701ヶ月の変化-13.16%3ヶ月変化-21.09%1年変化-24.97%3年間の変化134.70%5年間の変化-78.31%IPOからの変化-90.85%最新ニュースお知らせ • 20mVireo Growth Inc. (CNSX:VREO) and Vive Penn, LLC acquired FarmX, LLC.Vireo Growth Inc. (CNSX:VREO) and Vive Penn, LLC entered into a Securities Purchase Agreement to acquire FarmX, LLC for $20 million on July 2, 2026. The total consideration consists of $8 million in cash payable at closing and $12 million payable through the issuance of approximately 645,161 subordinate voting shares of Vireo. The stock consideration is scheduled to be issued two years following the closing date. Post-transaction, the acquired permit will allow Vive Penn, LLC to operate up to six retail medical dispensaries in Pennsylvania. The transaction is subject to approval by regulatory board / committee and customary closing conditions. The transaction is expected to close two business days following the date the parties satisfy all conditions precedent to the agreement. Vireo Growth Inc. (CNSX:VREO) and Vive Penn, LLC completed the acquisition of FarmX, LLC on July 17, 2026.お知らせ • Jun 17Vireo Growth Inc. (CNSX:VREO) entered into a definitive agreement to acquire C21 Investments Inc. (CNSX:CXXI) for $34.88 million.Vireo Growth Inc. (CNSX:VREO) entered into a definitive agreement to acquire C21 Investments Inc. (CNSX:CXXI) for $34.88 million on June 15, 2026. The consideration consists of 2.72 million common equity of Vireo Growth Inc. at a ratio of 0.023052 per common equity of C21 Investments Inc. As part of consideration, an undisclosed value is paid towards common equity of C21 Investments Inc. In case of termination of transaction, seller will pay a termination fee of $3 million. The transaction is subject to subject to court approval, approval by regulatory board, approval of merger agreement by target board, approval of offer by acquirer board and approval of offer by target shareholders. The Board of Directors of C21 Investments Inc. formed a special committee for the transaction. The deal has been unanimously approved by the board. The transaction is expected to close in the third quarter of 2026. Needham & Company, LLC acted as fairness opinion provider and Koffman Kalef LLP, Dorsey & Whitney LLP and DLA Piper LLP acted as legal advisors for C21 Investments Inc. Eversheds Sutherland LLP acted as legal advisor for Vireo Growth Inc.Buy Or Sell Opportunity • Jun 04Now 232% overvalued after recent price riseOver the last 90 days, the stock has risen 2,800% to CA$17.40. The fair value is estimated to be CA$5.24, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 51% over the last 3 years. Earnings per share has grown by 40%.お知らせ • May 26Vireo Growth Inc. (CNSX:VREO) signed a letter of intent to acquire Bridgewell Agribusiness LLC from Bwab Holdings, Llc for $40.3 million.Vireo Growth Inc. (CNSX:VREO) signed a letter of intent to acquire Bridgewell Agribusiness LLC from Bwab Holdings, Llc for $40.3 million on May 25, 2026. The consideration consists of convertible debt of Vireo Growth Inc. having a value of $10.26 million to be issued for common equity of Bridgewell Agribusiness LLC. The aggregate consideration for the Bridgewell Transaction is based on a base purchase price of US$40 million, subject to adjustments for, among other things, approximately US$30 million of assumed indebtedness of Bridgewell that will remain outstanding following closing and the assumption of certain other transaction expenses. After giving effect to such adjustments, the estimated closing purchase price is expected to be approximately US$10.26 million In exchange for the issued and outstanding membership interests of Bridgewell, Vireo will issue an unsecured, subordinated convertible note to the Seller (the “Convertible Note”) in the aggregate principal amount equal to the closing purchase price, which will automatically convert on or after the second anniversary of closing into an estimated 16,552,150 subordinate voting shares of Vireo (the “Consideration Shares”) at a deemed price of US$0.62 per Consideration Share (which final price will be subject to the policies of the Canadian Securities Exchange and based on the volume weighted average trading price of the Company’s subordinate voting shares for 20 consecutive trading days ending two trading days prior to the closing date). The aggregate principal amount of the Convertible Note and number of Consideration Shares issuable thereunder are subject to certain post-closing purchase price and other adjustments. The transaction is subject to approval by regulatory board / committee and definitive agreement. The Bridgewell Transaction could close any time following five (5) business days.Reported Earnings • May 13First quarter 2026 earnings released: US$0.019 loss per share (vs US$0.018 loss in 1Q 2025)First quarter 2026 results: US$0.019 loss per share (further deteriorated from US$0.018 loss in 1Q 2025). Revenue: US$106.2m (up 333% from 1Q 2025). Net loss: US$20.3m (loss widened 212% from 1Q 2025). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 33% per year, which means it is significantly lagging earnings growth.お知らせ • May 07Vireo Growth Inc. to Report Q1, 2026 Results on May 12, 2026Vireo Growth Inc. announced that they will report Q1, 2026 results Pre-Market on May 12, 2026最新情報をもっと見るRecent updatesお知らせ • 20mVireo Growth Inc. (CNSX:VREO) and Vive Penn, LLC acquired FarmX, LLC.Vireo Growth Inc. (CNSX:VREO) and Vive Penn, LLC entered into a Securities Purchase Agreement to acquire FarmX, LLC for $20 million on July 2, 2026. The total consideration consists of $8 million in cash payable at closing and $12 million payable through the issuance of approximately 645,161 subordinate voting shares of Vireo. The stock consideration is scheduled to be issued two years following the closing date. Post-transaction, the acquired permit will allow Vive Penn, LLC to operate up to six retail medical dispensaries in Pennsylvania. The transaction is subject to approval by regulatory board / committee and customary closing conditions. The transaction is expected to close two business days following the date the parties satisfy all conditions precedent to the agreement. Vireo Growth Inc. (CNSX:VREO) and Vive Penn, LLC completed the acquisition of FarmX, LLC on July 17, 2026.お知らせ • Jun 17Vireo Growth Inc. (CNSX:VREO) entered into a definitive agreement to acquire C21 Investments Inc. (CNSX:CXXI) for $34.88 million.Vireo Growth Inc. (CNSX:VREO) entered into a definitive agreement to acquire C21 Investments Inc. (CNSX:CXXI) for $34.88 million on June 15, 2026. The consideration consists of 2.72 million common equity of Vireo Growth Inc. at a ratio of 0.023052 per common equity of C21 Investments Inc. As part of consideration, an undisclosed value is paid towards common equity of C21 Investments Inc. In case of termination of transaction, seller will pay a termination fee of $3 million. The transaction is subject to subject to court approval, approval by regulatory board, approval of merger agreement by target board, approval of offer by acquirer board and approval of offer by target shareholders. The Board of Directors of C21 Investments Inc. formed a special committee for the transaction. The deal has been unanimously approved by the board. The transaction is expected to close in the third quarter of 2026. Needham & Company, LLC acted as fairness opinion provider and Koffman Kalef LLP, Dorsey & Whitney LLP and DLA Piper LLP acted as legal advisors for C21 Investments Inc. Eversheds Sutherland LLP acted as legal advisor for Vireo Growth Inc.Buy Or Sell Opportunity • Jun 04Now 232% overvalued after recent price riseOver the last 90 days, the stock has risen 2,800% to CA$17.40. The fair value is estimated to be CA$5.24, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 51% over the last 3 years. Earnings per share has grown by 40%.お知らせ • May 26Vireo Growth Inc. (CNSX:VREO) signed a letter of intent to acquire Bridgewell Agribusiness LLC from Bwab Holdings, Llc for $40.3 million.Vireo Growth Inc. (CNSX:VREO) signed a letter of intent to acquire Bridgewell Agribusiness LLC from Bwab Holdings, Llc for $40.3 million on May 25, 2026. The consideration consists of convertible debt of Vireo Growth Inc. having a value of $10.26 million to be issued for common equity of Bridgewell Agribusiness LLC. The aggregate consideration for the Bridgewell Transaction is based on a base purchase price of US$40 million, subject to adjustments for, among other things, approximately US$30 million of assumed indebtedness of Bridgewell that will remain outstanding following closing and the assumption of certain other transaction expenses. After giving effect to such adjustments, the estimated closing purchase price is expected to be approximately US$10.26 million In exchange for the issued and outstanding membership interests of Bridgewell, Vireo will issue an unsecured, subordinated convertible note to the Seller (the “Convertible Note”) in the aggregate principal amount equal to the closing purchase price, which will automatically convert on or after the second anniversary of closing into an estimated 16,552,150 subordinate voting shares of Vireo (the “Consideration Shares”) at a deemed price of US$0.62 per Consideration Share (which final price will be subject to the policies of the Canadian Securities Exchange and based on the volume weighted average trading price of the Company’s subordinate voting shares for 20 consecutive trading days ending two trading days prior to the closing date). The aggregate principal amount of the Convertible Note and number of Consideration Shares issuable thereunder are subject to certain post-closing purchase price and other adjustments. The transaction is subject to approval by regulatory board / committee and definitive agreement. The Bridgewell Transaction could close any time following five (5) business days.Reported Earnings • May 13First quarter 2026 earnings released: US$0.019 loss per share (vs US$0.018 loss in 1Q 2025)First quarter 2026 results: US$0.019 loss per share (further deteriorated from US$0.018 loss in 1Q 2025). Revenue: US$106.2m (up 333% from 1Q 2025). Net loss: US$20.3m (loss widened 212% from 1Q 2025). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 33% per year, which means it is significantly lagging earnings growth.お知らせ • May 07Vireo Growth Inc. to Report Q1, 2026 Results on May 12, 2026Vireo Growth Inc. announced that they will report Q1, 2026 results Pre-Market on May 12, 2026お知らせ • May 02Vireo Growth Inc. (CNSX:VREO) entered into a definitive arrangement agreement to acquire FLUENT Corp. (CNSX:FNT.U) for $19.2 million.Vireo Growth Inc. (CNSX:VREO) entered into a definitive arrangement agreement to acquire FLUENT Corp. (CNSX:FNT.U) for $19.2 million on April 30, 2026. As part of the acquisition, Vireo Growth Inc. will acquire all of the issued and outstanding common shares of FLUENT Corp. As part of consideration, each shareholder of FLUENT Corp will receive 0.0705359 of a subordinate voting share of Vireo Growth Inc in exchange for each FLUENT Corp Share held. Following the completion of the Transaction, FLUENT will join the Vireo ecosystem and gain exposure to a larger and well capitalized multi-state operator currently operating in 10 states across the U.S. In connection with the Transaction, Vireo has entered into voting support agreements with certain directors, officers and key shareholders of FLUENT, with such holders representing approximately 38.3% of the issued and outstanding FLUENT Shares, pursuant to which they have agreed to, among other things, vote their FLUENT Shares in favor of the Transaction. Chris Hagedorn has resigned from the FLUENT Board. The vacancy will not be filled at this time. Upon completion, it is expected that the FLUENT Shares will be delisted from the Canadian Securities Exchange (“CSE”) and the OTCQB Venture Market and that FLUENT will apply to cease to be a reporting issuer under applicable Canadian securities laws. In case of termination of transaction, FLUENT Corp. will pay a termination fee of $2 million to Vireo Growth Inc. The transaction is subject to court approvals, as well as the receipt of all required regulatory approvals, the completion of the Equitization, and the satisfaction of certain other closing conditions customary in transactions of this nature, approval by the shareholders of FLUENT Corp and other third-party approvals. The Board of Directors of FLUENT Corp. formed a special committee for the transaction. The Special Committee and the FLUENT Board have unanimously determined that the Transaction is in the best interests of FLUENT and is fair to the FLUENT Shareholders and the FLUENT Board recommends that the FLUENT Shareholders vote in favor of the Transaction. The transaction is expected to close in the fourth quarter of 2026. ATB Cormark Capital Markets acted as fairness opinion provider to the Special Committee and board of directors of FLUENT Corp. ATB Cormark Capital Markets acted as financial advisor to the Special Committee of FLUENT Corp. Cassels Brock & Blackwell LLP acted as legal advisor to FLUENT Corp. Goodwin Procter LLP acted as legal advisor to FLUENT Corp. DLA Piper (Canada) LLP acted as legal advisor to Vireo Growth Inc. Eversheds Sutherland (US) LLP acted as legal advisor to Vireo Growth Inc. Shenker Russo & Clark LLP acted as legal advisor to Vireo Growth Inc. Foley & Lardner LLP acted as legal advisor to Vireo Growth Inc.お知らせ • Apr 17Vireo Growth Inc. announced that it has received $50.612571 million in fundingOn April 16, 2026. Vireo Growth Inc. announced that it has closed the transaction.お知らせ • Apr 09Vireo Growth Inc. (CNSX : VREO) completed the acquisition of The Hawthorne Gardening Company from Smg Growing Media, Inc. for 84.6 million.Vireo Growth Inc. (CNSX : VREO) entered into a nonbinding memorandum of understanding to acquire The Hawthorne Gardening Company from Smg Growing Media, Inc. for approximately $120 million on January 15, 2026. As part of consideration Vireo Growth Inc. issued 206 million ordinary shares, a warrant to purchase 80 million at an exercise price of $0.85 per Share, exercisable for a period of five years from the date of issuance. Additional Vireo Growth Inc. acquire The Hawthorne Gardening Company $35 million of cash, approximately $50 million of net working capital, and would be provided approximately $20 million of inventory. Vireo intends to name Chris Hagedorn, Executive Vice President of ScottsMiracle-Gro and Executive Lead of the Hawthorne business, to its Board of Directors upon completion of the transition upon completion of the transaction and shareholder approval. The transaction is subjected to regulatory approvals and the finalization of a definitive agreement. If applicable, the approval of the Canadian Securities Exchange. The expected to be completed during the second quarter of 2026. Vireo Growth Inc. (CNSX : VREO) completed the acquisition of The Hawthorne Gardening Company from Smg Growing Media, Inc. for 84.6 million on April 8, 2026. Under the terms of the transaction, Vireo Growth Inc. acquired $35 million of cash held by Hawthorne, and issued 213 million of its subordinate voting shares and a warrant to purchase 80 million at an exercise price of $0.85 per Share.お知らせ • Apr 01Vireo Growth Inc. Announces Cory Azzalino to Step into the CEO Role of Vireo’s California BusinessVireo Growth Inc. announced Cory Azzalino will step into the CEO role of Vireo’s California business – Cory and his team bring operational acumen and emphasis on retail excellence which strengthens Vireo’s platform.Reported Earnings • Mar 18Full year 2025 earnings released: US$0.093 loss per share (vs US$0.15 loss in FY 2024)Full year 2025 results: US$0.093 loss per share. Revenue: US$268.8m (up 170% from FY 2024). Net loss: US$68.1m (loss widened 143% from FY 2024). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 10.0% growth forecast for the Pharmaceuticals industry in Canada.お知らせ • Mar 17Vireo Growth Inc., Annual General Meeting, May 29, 2026Vireo Growth Inc., Annual General Meeting, May 29, 2026.お知らせ • Mar 10Vireo Growth Inc. to Report Q4, 2025 Results on Mar 17, 2026Vireo Growth Inc. announced that they will report Q4, 2025 results Pre-Market on Mar 17, 2026お知らせ • Jan 28Vireo Growth Inc. (CNSX : VREO) entered into a nonbinding Memorandum of Understanding to acquire The Hawthorne Gardening Company from Smg Growing Media, Inc.Vireo Growth Inc. (CNSX : VREO) entered into a nonbinding memorandum of understanding to acquire The Hawthorne Gardening Company from Smg Growing Media, Inc. on January 28, 2026. Upon completion, Vireo intends to name Chris Hagedorn, Executive Vice President of ScottsMiracle-Gro and Executive Lead of the Hawthorne business, to its Board of Directors.Recent Insider Transactions Derivative • Jan 02President exercised options and sold CA$104k worth of stockOn the 29th of December, Amber Shimpa exercised options to acquire 127k shares at no cost and sold these for an average price of CA$0.82 per share. This trade did not impact their existing holding. Since March 2025, Amber's direct individual holding has increased from 875.63k shares to 1.97m. This was the only transaction from an insider over the last 12 months.分析記事 • Dec 30Vireo Growth Inc.'s (CSE:VREO) 38% Jump Shows Its Popularity With InvestorsVireo Growth Inc. ( CSE:VREO ) shareholders are no doubt pleased to see that the share price has bounced 38% in the...お知らせ • Dec 23Vireo Growth Inc. (CNSX:VREO) agreed to acquire Eaze Technologies, Inc. for $48.9 million.Vireo Growth Inc. (CNSX:VREO) agreed to acquire Eaze Technologies, Inc. for $48.9 million on December 22, 2025. The consideration is payable through the issuance of approximately 84 million subordinate voting shares of the Vireo at closing. Total consideration payable in the transaction will be subject to adjustment based on closing levels of cash, indebtedness, tax obligations and working capital adjustments, as well as the occurrence of certain other events by the closing date. Eaze may be entitled to earn-out consideration as of December 31, 2026. Eaze will become a wholly-owned subsidiary of Vireo. The expected completion of the transaction is January 1, 2026 to June 30, 2026.お知らせ • Dec 18Vireo Growth Inc. (CNSX:VREO) entered into an asset purchase agreement to acquire Certain retail assets and properties of PharmaCann Inc. for $49 million.Vireo Growth Inc. (CNSX:VREO) entered into an asset purchase agreement to acquire Certain retail assets and properties of PharmaCann Inc. for $49 million on December 16, 2025. Total consideration is payable in subordinate voting shares of the Vireo Growth, as well as the assumption of certain liabilities. The transaction is subject to satisfaction of closing conditions and state and local regulatory approvals. The transaction is expected to close during the first half of calendar year 2026.分析記事 • Nov 15With A 35% Price Drop For Vireo Growth Inc. (CSE:VREO) You'll Still Get What You Pay ForThe Vireo Growth Inc. ( CSE:VREO ) share price has fared very poorly over the last month, falling by a substantial 35...New Risk • Nov 14New major risk - Revenue and earnings growthEarnings have declined by 1.2% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 1.2% per year over the past 5 years. Shareholders have been substantially diluted in the past year (362% increase in shares outstanding).Reported Earnings • Nov 14Third quarter 2025 earnings released: US$0.042 loss per share (vs US$0.024 loss in 3Q 2024)Third quarter 2025 results: US$0.042 loss per share (further deteriorated from US$0.024 loss in 3Q 2024). Revenue: US$91.7m (up 264% from 3Q 2024). Net loss: US$26.3m (loss widened 434% from 3Q 2024). Revenue is forecast to grow 66% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.お知らせ • Oct 31Vireo Growth Inc. to Report Q3, 2025 Results on Nov 12, 2025Vireo Growth Inc. announced that they will report Q3, 2025 results After-Market on Nov 12, 2025お知らせ • Oct 29Vireo Growth Inc. and Verano Holdings Corp. Reaches Comprehensive Settlement Dismissing All Outstanding Litigation MattersVireo Growth Inc. and Verano Holdings Corp. on October 29, 2025 announced that they have reached a comprehensive settlement dismissing all outstanding litigation matters between the two Companies that are pending before the Supreme Court of British Columbia, Canada. The terms of the Settlement Agreement were approved by the respective Boards of Directors of both Companies. The value of the settlement to Vireo is approximately USD 10 million consisting of the acquisition of certain real estate assets and USD 1 million in cash. The resolution marks the conclusion of a complex legal chapter and reflects a commitment by both Companies to move forward in a constructive manner. Both Companies reiterated their dedication to delivering long-term value to their shareholders and quality products and services to their customers.お知らせ • Oct 24Vireo Growth Inc. announced that it has received $61.996221 million in fundingOn October 23, 2025, Vireo Growth Inc closed the transaction. The transaction included participation from 22 investors.お知らせ • Sep 16Vireo Growth Inc. Announces Launch of Adult-Use Cannabis Sales in MinnesotaVireo Growth Inc. announced that on September 16, 2025, it recorded its first sale of adult use cannabis in Minnesota at its historic downtown Minneapolis Green Goods® dispensary. The Company is now dispensing a full suite of both medical and adult-use cannabis products at all eight of its Green Goods™ dispensaries located throughout the State of Minnesota. Vireo has been operating in Minnesota’s medical cannabis market since 2014, serving tens of thousands of patients with safe, reliable products. The Company is committed to expanding access, improving product quality, and supporting the state’s transition to a sustainable, locally driven adult-use market. As one of the state’s operational licensed adult-use cannabis cultivators and retailers, and a population of 5.7 million people, the launch of Minnesota’s adult-use cannabis market is expected to serve as a strong organic revenue growth catalyst for Vireo for the foreseeable future. Green Goods® offers a full suite of medical and adult-use cannabis products and form factors including flower, pre-rolls, edibles, and beverages, and currently operates eight retail dispensaries in Minnesota. Green Goods® dispensaries are located in Minneapolis, Blaine, Bloomington, Burnsville, Duluth, Moorhead, Rochester, and Woodbury. For more information about Green Goods or to shop its product menu, please visit www.visitgreengoods.com.分析記事 • Sep 11With A 33% Price Drop For Vireo Growth Inc. (CSE:VREO) You'll Still Get What You Pay ForVireo Growth Inc. ( CSE:VREO ) shares have retraced a considerable 33% in the last month, reversing a fair amount of...Reported Earnings • Aug 14Second quarter 2025 earnings released: US$0.027 loss per share (vs US$0.005 loss in 2Q 2024)Second quarter 2025 results: US$0.027 loss per share (further deteriorated from US$0.005 loss in 2Q 2024). Revenue: US$48.1m (up 91% from 2Q 2024). Net loss: US$14.9m (loss widened US$14.3m from 2Q 2024). Revenue is forecast to grow 78% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.お知らせ • Aug 05Vireo Growth Inc. to Report Q2, 2025 Results on Aug 13, 2025Vireo Growth Inc. announced that they will report Q2, 2025 results Pre-Market on Aug 13, 2025お知らせ • Jul 10Vireo Growth Inc. announced that it has received $10 million in funding from Chicago Atlantic Opportunity Finance, LLCVireo Growth Inc announced that it has completed a private placement and issued $10,000,000 principal amount of convertible Notes on July 9, 2025. The Notes are convertible into an aggregate of 16,000,000 Shares upon exercise. The new convertible note was issued in reliance upon exemptions from the registration requirements of the U.S. Securities Act of 1933, as amended and applicable Canadian and U.S state Securities laws. The transaction included participation from Chicago Atlantic Opportunity Finance, LLC.お知らせ • Jun 10Vireo Growth Inc. (CNSX:VREO) completed the acquisition of Deep Roots Harvest, Inc. for $64.14 million.Vireo Growth Inc. (CNSX:VREO) has signed definitive agreement to acquire Deep Roots Harvest, Inc. on December 18, 2024. Total consideration is approximately $397 million of all-stock transactions. In Related transactions Vireo has signed definitive agreements to acquire Proper Brands in Missouri and WholesomeCo Cannabis in Utah, while also signing a binding MOU to acquire The Flowery in Florida. Vireo estimates proforma revenue and EBITDA of the combined company of approximately $394 million and $94 million, respectively, for calendar year 2024. Upon closing of the Merger Transactions, Vireo estimates the combined company will be well-positioned for further growth with a favorable balance sheet consisting of approximately $99 million of cash and $78 million of net debt with an EBITDA leverage ratio of approximately 0.8x. The Proper Brands, Deep Roots Harvest and WholesomeCo Cannabis are expected to be acquired at a multiple of 4.175x 2024 “Reference EBITDA” pro-forma for pending acquisitions as well as planned new retail openings and expansion projects. Each transaction has been based on a $0.52 Vireo share reference price. The Deep Roots Merger Agreement also contains customary indemnification obligations of Vireo and Deep Roots, other obligations of the parties and termination provisions, under which, subject to certain conditions and in certain instances of termination, would require Vireo or Deep Roots to pay a termination fee equal to $6.37624 million. These acquisition targets may qualify for earnout payments on December 31, 2026, based on 4x EBITDA growth compared to Reference EBITDA, adjusted for incremental debt, and paid out using a share price at the higher of $1.05 or 20-day VWAP as of December 31, 2026. Reference EBITDA for Proper Brands, Deep Roots Harvest and WholesomeCo Cannabis are $31.0 million, $31.0 million, and $16.0 million, respectively. John Mazarakis, co-founder at Chicago Atlantic, has been appointed to the role of Chief Executive Officer and Co-Executive Chairman, effective immediately. Tyson Macdonald, former partner at TrueRise Capital, has been appointed to the role of Chief Financial Officer, effective immediately. Amber Shimpa will continue to serve as President of the Company and as Chief Executive Officer of Minnesota, Maryland, and New York. Implementation of the Merger Transactions are subject to the approval of holders of a majority of Vireo's voting shares and regulatory approvals. The Merger Transactions have been unanimously approved by the Boards of Directors of Vireo and each of the target acquisition companies. Vireo anticipates that closing of all of the Merger Transactions to take at least six months pending shareholder and regulatory approvals. Vireo expects that each transaction will be accretive to the broader portfolio. Moelis & Company LLC acted as fairness opinion provider for Boards of Directors of Vireo Growth Inc. Moelis & Company LLC acted as financial advisor for Vireo Growth Inc. Dorsey & Whitney LLP acted as legal advisor for Vireo Growth Inc. Vireo Growth Inc. (CNSX:VREO) completed the acquisition of Deep Roots Harvest, Inc. for $64.14 million on June 9, 2025. Total consideration for the transaction is paid in the form of 255.2 million Subordinate Voting Shares of Vireo at a reference price per share of $0.52. The purchase price of the Deep Roots transaction represents a multiple of 4.175x 2024 “Closing EBITDA” of $30 million.お知らせ • Jun 06Vireo Growth Inc. (CNSX:VREO) completed the acquisition of Proper Brands for $73.3 million.Vireo Growth Inc. (CNSX:VREO) entered into a definitive agreement to acquire Proper Brands on December 18, 2024. Under the terms of the transaction, the transaction is expected to be effected by way of an all-stock transaction, and The Proper Brands, Deep Roots Harvest and WholesomeCo Cannabis are expected to be acquired at a multiple of 4.175x 2024 “Reference EBITDA” pro-forma for pending acquisitions as well as planned new retail openings and expansion projects. Each transaction has been based on a $0.52 Vireo share reference price. Reference EBITDA for Proper Brands is $31.0 million. Vireo will include in the stock merger consideration calculation an amount equal to $2,139,200 for the stockholders of Proper Brands for all of the outstanding equity interests in Arches IP, Inc. owned by Proper Brands with a potential for earnout payments based on performance through December 31, 2026, based on the greater of $37.5 million or 5x revenue measured at the higher of trailing-twelve-month or nine-month annualized net revenues, paid out using a share price at the higher of $1.05 or 20-day VWAP as of December 31, 2026. The seller of Proper Brand has agreed to voluntary share lock-up after 33 months of consummation. In separate transactions, Vireo will also acquire Deep Roots Harvest, WholesomeCo Cannabis, and The Flowery. The transaction is subject to approval by regulatory board, approval of merger agreement by target board, approval of offer by acquirer board, subject to shareholder approval and lock-up agreement, and a clawback provision if they perform below the respective Reference EBITDA measured as the higher of trailing twelve-months or nine-months annualized EBITDA as of December 31, 2026, adjusted for any intercompany funding. The Merger Transactions have been unanimously approved by the Boards of Directors of Vireo and Proper Brands. In certain instances of termination, Vireo or Proper Brands is required to pay a termination fee equal to $4,631,012. Moelis & Company LLC acted as financial advisor and Fairness Opinion Provider, and Nicole Stanton of Dorsey & Whitney LLP acted as legal advisor to Vireo. Lineage Merchant Partners, LLC acted as placement agent for the financing. Vireo Growth Inc. (CNSX:VREO) completed the acquisition of Proper Brands for $73.3 million on June 5, 2025. Total consideration for the transactions was $102 million, paid in the form of 196.2 million Subordinate Voting Shares of Vireo at a reference price per share of $0.52.お知らせ • May 13Vireo Growth Inc. (CNSX:VREO) completed the acquisition of WholesomeCo Cannabis.Vireo Growth Inc. (CNSX:VREO) signed an agreement to acquire WholesomeCo Cannabis on December 18, 2024. Vireo has signed three definitive documents and one binding Memorandum of Understanding to acquire four single-state operators (Proper Brands, Deep Roots Harvest, and Bill’s Nursery, Inc, WholesomeCo Cannabis) for total consideration of approximately $397 million in a series of all-stock transactions and may qualify for earnout payments on December 31, 2026. Vireo will include in the stock merger consideration calculation an amount equal to $11,860,800 for the stockholders of WholesomeCo Cannabis for all of the outstanding equity interests in Arches IP, Inc. owned by WholesomeCo Cannabis with a potential for earnout payments based on performance through December 31, 2026, based on the greater of $37.5 million or 5x revenue measured at the higher of trailing-twelve-month or nine-month annualized net revenues, paid out using a share price at the higher of $1.05 or 20-day VWAP as of December 31, 2026. The transaction is subject to certain shareholder and regulatory approvals, and clawback provision. In certain instances of termination, Vireo or WholesomeCo Cannabis is required to pay a termination fee equal to $3,394,217. The Merger Transactions have been unanimously approved by the Boards of Directors of Vireo and WholesomeCo Cannabis. As of March 9, 2025, Vireo Growth Inc. has obtained required regulatory approvals and is working toward satisfying all other customary closing conditions, which it expects to meet during the second quarter of 2025. Moelis & Company LLC acted as financial advisor and fairness opinion provider, and Nicole Stanton of Dorsey & Whitney LLP acted as legal advisor to Vireo. Lineage Merchant Partners, LLC acted as placement agent for the financing. Adam Hull of Polsinelli PC acted as legal advisor to WholesomeCo. Vireo Growth Inc. (CNSX:VREO) completed the acquisition of WholesomeCo Cannabis for $69.8 million on May 12, 2025. $69.8 million paid in the form of 134.2 million Subordinate Voting Shares of Vireo at a reference price per share of $0.52.Reported Earnings • May 10First quarter 2025 earnings released: US$0.018 loss per share (vs US$0.047 loss in 1Q 2024)First quarter 2025 results: US$0.018 loss per share (improved from US$0.047 loss in 1Q 2024). Revenue: US$24.5m (up 1.9% from 1Q 2024). Net loss: US$6.51m (loss narrowed 3.0% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.お知らせ • Apr 29Vireo Growth Inc. to Report Q1, 2025 Results on May 09, 2025Vireo Growth Inc. announced that they will report Q1, 2025 results Pre-Market on May 09, 2025お知らせ • Apr 09Vireo Growth Inc., Annual General Meeting, Jun 20, 2025Vireo Growth Inc., Annual General Meeting, Jun 20, 2025.分析記事 • Apr 04Revenues Not Telling The Story For Vireo Growth Inc. (CSE:VREO) After Shares Rise 26%Vireo Growth Inc. ( CSE:VREO ) shareholders are no doubt pleased to see that the share price has bounced 26% in the...分析記事 • Mar 31Is Vireo Growth (CSE:VREO) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Reported Earnings • Mar 04Full year 2024 earnings released: US$0.15 loss per share (vs US$0.19 loss in FY 2023)Full year 2024 results: US$0.15 loss per share. Revenue: US$99.4m (up 13% from FY 2023). Net loss: US$28.0m (loss widened 9.6% from FY 2023). Revenue is forecast to grow 8.1% p.a. on average during the next 2 years, compared to a 7.9% growth forecast for the Pharmaceuticals industry in Canada.お知らせ • Feb 20Vireo Growth Inc. to Report Q4, 2024 Results on Mar 04, 2025Vireo Growth Inc. announced that they will report Q4, 2024 results Pre-Market on Mar 04, 2025お知らせ • Jan 01Vireo Growth Inc. announced that it has received $80.960546 million in fundingOn December 30, 2024, Vireo Growth Inc., closed the transaction. The company issued 129,536,874 subordinate voting shares at a price of $0.625 per share for the gross proceeds of $80,960,546.25 in the transaction. The transaction has been oversubscribed.お知らせ • Dec 19+ 4 more updatesVireo Growth Inc. (CNSX:VREO) entered into a definitive agreement to acquire Proper Brands.Vireo Growth Inc. (CNSX:VREO) entered into a definitive agreement to acquire Proper Brands on December 18, 2024. Under the terms of the transaction, the transaction is expected to be effected by way of an all-stock transaction, and The Proper Brands, Deep Roots Harvest and WholesomeCo Cannabis are expected to be acquired at a multiple of 4.175x 2024 “Reference EBITDA” pro-forma for pending acquisitions as well as planned new retail openings and expansion projects. Each transaction has been based on a $0.52 Vireo share reference price. These acquisition targets may qualify for earnout payments on December 31, 2026, based on 4x EBITDA growth compared to Reference EBITDA, adjusted for incremental debt, and paid out using a share price at the higher of $1.05 or 20-day VWAP as of December 31, 2026. Reference EBITDA for Proper Brands is$31.0 million. Total payment for Arches includes $14 million in upfront consideration to WholesomeCo and Proper Brands with a potential for earnout payments based on performance through December 31, 2026, based on the greater of $37.5 million or 5x revenue measured at the higher of trailing-twelve-month or nine-month annualized net revenues, paid out using a share price at the higher of $1.05 or 20-day VWAP as of December 31, 2026. The seller of Bill's Nursery has agreed to voluntary share lock-up after 33 months of consummation. In separate transactions, Vireo will also acquire Deep Roots Harvest, WholesomeCo Cannabis, and The Flowery. The transaction is subject to approval by regulatory board, approval of merger agreement by target board, approval of offer by acquirer board, subject to shareholder approval and lock-up agreement, and a clawback provision if they perform below the respective Reference EBITDA measured as the higher of trailing twelve-months or nine-months annualized EBITDA as of December 31, 2026, adjusted for any intercompany funding. The Merger Transactions have been unanimously approved by the Boards of Directors of Vireo and Bill's Nursery. Moelis & Company LLC acted as financial advisor and Fairness Opinion Provider, and Dorsey & Whitney LLP acted as legal advisor to Vireo. Lineage Merchant Partners, LLC acted as placement agent for the financing.分析記事 • Nov 27Risks Still Elevated At These Prices As Vireo Growth Inc. (CSE:VREO) Shares Dive 26%Vireo Growth Inc. ( CSE:VREO ) shareholders that were waiting for something to happen have been dealt a blow with a 26...Reported Earnings • Nov 15Third quarter 2024 earnings released: US$0.024 loss per share (vs US$0.037 loss in 3Q 2023)Third quarter 2024 results: US$0.024 loss per share (improved from US$0.037 loss in 3Q 2023). Revenue: US$25.2m (up 2.0% from 3Q 2023). Net loss: US$4.93m (loss narrowed 5.8% from 3Q 2023). Revenue is forecast to grow 3.4% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings.お知らせ • Nov 05Vireo Growth Inc. announced that it expects to receive $10 million in fundingVireo Growth Inc. announced that it has secured a new convertible debt facility which provides a financing commitment of up to $10,000,000 in aggregate principal amount of convertible notes on November 4, 2024. This facility is being funded by the Company’s senior secured lender and its affiliates under the Company’s existing credit agreement. The convertible facility has a term of three years, with a cash interest rate of 12.0 percent, and such interest shall be paid to Lender in cash on the last business day of each calendar month. The Convertible Notes shall be convertible at any time into Subordinate Voting Shares of the Company, at the option of Lender, in whole but not in part, in a single transaction, at a conversion price equal to $0.625.お知らせ • Oct 30Vireo Growth Inc. to Report Q3, 2024 Results on Nov 13, 2024Vireo Growth Inc. announced that they will report Q3, 2024 results After-Market on Nov 13, 2024New Risk • Oct 13New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: CA$110.5m (US$80.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$23m). Shareholders have been substantially diluted in the past year (61% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (17% average weekly change). Market cap is less than US$100m (CA$110.5m market cap, or US$80.3m).分析記事 • Oct 12Vireo Growth Inc.'s (CSE:VREO) 29% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatioVireo Growth Inc. ( CSE:VREO ) shares have had a horrible month, losing 29% after a relatively good period beforehand...お知らせ • Oct 11+ 1 more updateVireo Growth Inc. Announces CFO ChangesVireo Growth Inc. announced several leadership updates. Josh Rosen has resigned from the Company's interim Chief Financial Officer, effective immediately, to focus on his other business ventures. Mr. Rosen was first elected to the Board in August 2021, and appointed to executive leadership roles in November 2022, including, most recently, the roles of Chief Executive Officer and interim Chief Financial Officer. The Company has engaged Mr. Rosen going forward with a consulting agreement. Joe Duxbury has been appointed as Interim Chief Financial Officer while the Company searches for a permanent replacement. Mr. Duxbury has been with the Company since 2019 in financial and accounting roles of increasing responsibility, and most recently was serving as Vice President of Finance leading external reporting and investor relations.お知らせ • Oct 10Vireo Growth Inc. Announces Resignation of Josh Rosen as DirectorVireo Growth Inc. announced several leadership updates. Josh Rosen has resigned from the Company's Board of Directors, effective immediately, to focus on his other business ventures. Mr. Rosen was first elected to the Board in August 2021, and appointed to executive leadership roles in November 2022, including, most recently, the roles of Chief Executive Officer and interim Chief Financial Officer. The Company has engaged Mr. Rosen going forward with a consulting agreement.Board Change • Sep 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. CEO, Interim CFO & Director Josh Rosen was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.New Risk • Aug 21New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 61% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$23m). Shareholders have been substantially diluted in the past year (61% increase in shares outstanding). Minor Risk Share price has been volatile over the past 3 months (15% average weekly change).お知らせ • Aug 20Vireo Growth Inc. announced that it has received $5.3875 million in fundingOn August 20, 2024, Vireo Growth Inc. closed the transaction. The transaction included participation from 14 investors.分析記事 • Aug 10Vireo Growth Inc. (CSE:VREO) Stock Rockets 25% As Investors Are Less Pessimistic Than ExpectedVireo Growth Inc. ( CSE:VREO ) shares have had a really impressive month, gaining 25% after a shaky period beforehand...Reported Earnings • Aug 07Second quarter 2024 earnings released: US$0.005 loss per share (vs US$0.057 loss in 2Q 2023)Second quarter 2024 results: US$0.005 loss per share (improved from US$0.057 loss in 2Q 2023). Revenue: US$25.1m (up 24% from 2Q 2023). Net loss: US$668.4k (loss narrowed 91% from 2Q 2023). Revenue is expected to decline by 1.4% p.a. on average during the next 2 years, while revenues in the Pharmaceuticals industry in Canada are expected to grow by 11%. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings.お知らせ • Jul 23Vireo Growth Inc. to Report Q2, 2024 Results on Aug 06, 2024Vireo Growth Inc. announced that they will report Q2, 2024 results After-Market on Aug 06, 2024分析記事 • Jun 01Market Might Still Lack Some Conviction On Goodness Growth Holdings, Inc. (CSE:GDNS) Even After 30% Share Price BoostGoodness Growth Holdings, Inc. ( CSE:GDNS ) shares have continued their recent momentum with a 30% gain in the last...お知らせ • May 31Goodness Growth Holdings, Inc. announced that it expects to receive $0.7 million in fundingGoodness Growth Holdings, Inc. announced a non-brokered private placement of its subordinate voting shares for the gross proceeds of $700,000 on May 30, 2024. The company expects that this transaction will be completed within the next five business days. All of the subordinate voting shares issued in connection with this private placement will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation.Reported Earnings • May 08First quarter 2024 earnings released: US$0.047 loss per share (vs US$0.066 loss in 1Q 2023)First quarter 2024 results: US$0.047 loss per share (improved from US$0.066 loss in 1Q 2023). Revenue: US$24.1m (up 26% from 1Q 2023). Net loss: US$6.71m (loss narrowed 20% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 34% per year, which means it is performing significantly worse than earnings.お知らせ • May 03+ 1 more updateGoodness Growth Holdings, Inc. Appoints Josh Rosen as Chief Executive OfficerGoodness Growth Holdings, Inc. announced several leadership and corporate updates related to the day-to-day management of its business. Josh Rosen, who has served as Interim CEO since February of 2023, has been appointed as Chief Executive Officer, effective immediately. Josh Rosen’s leadership over the course of the past 14 months has been instrumental in securing a path forward for Company as a standalone enterprise. The company have been immensely impressed with Josh’s stewardship of the organization through the exceptionally challenging circumstances that were created by Verano’s wrongful termination of merger agreement. During his tenure as Interim CEO, he has significantly improved fundamental operating and financial performance, and has represented the Company admirably in his interactions with both internal and external stakeholders.お知らせ • May 01Goodness Growth Holdings, Inc. to Report Q1, 2024 Results on May 07, 2024Goodness Growth Holdings, Inc. announced that they will report Q1, 2024 results After-Market on May 07, 2024お知らせ • Apr 13Goodness Growth Holdings, Inc., Annual General Meeting, Jun 21, 2024Goodness Growth Holdings, Inc., Annual General Meeting, Jun 21, 2024.分析記事 • Apr 06Goodness Growth Holdings, Inc. (CSE:GDNS) Stock Rockets 30% But Many Are Still Ignoring The CompanyDespite an already strong run, Goodness Growth Holdings, Inc. ( CSE:GDNS ) shares have been powering on, with a gain of...お知らせ • Apr 03Goodness Growth Holdings, Inc. Reports Impairment Charges for the Fourth Quarter Ended December 31, 2023Goodness Growth Holdings, Inc. reported impairment charges for the fourth quarter ended December 31, 2023. For the period, the company reported loss on impairment of long-lived assets of USD 411,629 compared to USD 1,119,583 last year same period.Reported Earnings • Apr 02Full year 2023 earnings released: US$0.19 loss per share (vs US$0.33 loss in FY 2022)Full year 2023 results: US$0.19 loss per share (improved from US$0.33 loss in FY 2022). Revenue: US$88.1m (up 18% from FY 2022). Net loss: US$25.5m (loss narrowed 40% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 44% per year, which means it is performing significantly worse than earnings.お知らせ • Mar 15Goodness Growth Holdings, Inc. to Report Q4, 2023 Results on Mar 28, 2024Goodness Growth Holdings, Inc. announced that they will report Q4, 2023 results at 4:00 PM, US Eastern Standard Time on Mar 28, 2024分析記事 • Feb 01Investors Still Aren't Entirely Convinced By Goodness Growth Holdings, Inc.'s (CSE:GDNS) Revenues Despite 59% Price JumpGoodness Growth Holdings, Inc. ( CSE:GDNS ) shares have continued their recent momentum with a 59% gain in the last...お知らせ • Dec 15Goodness Growth Holdings, Inc. Announces Departure of Michael Schroeder as General Counsel & Chief Compliance Officer Effective December 15, 2023Goodness Growth Holdings, Inc. announced that the Company’s General Counsel and Chief Compliance Officer, Michael Schroeder, will depart the Company effective December 15, 2023 to accept an external opportunity at Venture Medical, LLC, a national medical devices and wound care products distributor located in Missoula, Montana. The Company plans to retain external legal counsel on an interim basis to fulfill Mr. Schroeder’s former duties as General Counsel until a permanent successor can be identified, and will continue conducting its compliance procedures through a mix of existing internal and external resources.Reported Earnings • Nov 17Third quarter 2023 earnings released: US$0.037 loss per share (vs US$0.066 loss in 3Q 2022)Third quarter 2023 results: US$0.037 loss per share (improved from US$0.066 loss in 3Q 2022). Revenue: US$24.7m (up 31% from 3Q 2022). Net loss: US$5.23m (loss narrowed 38% from 3Q 2022). Revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 44% per year, which means it is performing significantly worse than earnings.お知らせ • Nov 03Goodness Growth Holdings, Inc. to Report Q3, 2023 Results on Nov 14, 2023Goodness Growth Holdings, Inc. announced that they will report Q3, 2023 results After-Market on Nov 14, 2023お知らせ • Sep 28Goodness Growth Holdings, Inc. Announces CFO ChangesGoodness Growth Holdings, Inc. announced that Chief Financial Officer, John Heller, will depart the Company effective September 30 to accept a new external opportunity. Interim Chief Executive Officer Josh Rosen will assume the additional role of Interim Chief Financial Officer.New Risk • Aug 16New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$15m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$15m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Negative equity (-US$7.9m). Earnings have declined by 17% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (CA$25.4m market cap, or US$18.9m).Reported Earnings • Aug 15Second quarter 2023 earnings released: US$0.084 loss per share (vs US$0.048 loss in 2Q 2022)Second quarter 2023 results: US$0.084 loss per share (further deteriorated from US$0.048 loss in 2Q 2022). Revenue: US$20.2m (down 4.2% from 2Q 2022). Net loss: US$7.33m (loss widened 19% from 2Q 2022). Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.お知らせ • Aug 01Goodness Growth Holdings, Inc. to Report Q2, 2023 Results on Aug 14, 2023Goodness Growth Holdings, Inc. announced that they will report Q2, 2023 results After-Market on Aug 14, 2023New Risk • Jul 22New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 11% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Negative equity (-US$2.1m). Earnings have declined by 19% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (11% increase in shares outstanding). Market cap is less than US$100m (CA$27.8m market cap, or US$21.1m).Reported Earnings • May 17First quarter 2023 earnings released: US$0.066 loss per share (vs US$0.11 loss in 1Q 2022)First quarter 2023 results: US$0.066 loss per share (improved from US$0.11 loss in 1Q 2022). Revenue: US$19.1m (up 22% from 1Q 2022). Net loss: US$8.41m (loss narrowed 42% from 1Q 2022). Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.お知らせ • May 10Goodness Growth Holdings, Inc. to Report Q1, 2023 Results on May 15, 2023Goodness Growth Holdings, Inc. announced that they will report Q1, 2023 results at 4:00 PM, US Eastern Standard Time on May 15, 2023お知らせ • Feb 15+ 1 more updateGoodness Growth Holdings, Inc. Announces Management ChangesGoodness Growth Holdings, Inc. announced that Company founder, Dr. Kyle Kingsley, will assume the role of Executive Chairman. Chief Administrative Officer Amber Shimpa has been promoted to the role of President of the Company.Price Target Changed • Jan 13Price target decreased to CA$0.85Down from CA$1.00, the current price target is provided by 1 analyst. New target price is 270% above last closing price of CA$0.23. The company posted a net loss per share of US$0.27 last year.お知らせ • Dec 10Goodness Growth Holdings, Inc. Announces Departure of Christian Gonzalez-Ocasio as Chief Operating OfficerGoodness Growth Holdings, Inc. announced the departure of Chief Operating Officer, Christian Gonzalez-Ocasio. The Company intends to engage Mr. Gonzalez as a consultant for an interim period to help ensure a smooth transition with the Company's leadership team. Mr. Gonzalez had been serving as Chief Operating Officer of the Company since November 2020. He previously served as Executive Vice President of Operations, supporting manufacturing and retail initiatives, beginning in October 2019. The Company does not plan to immediately seek a replacement for the Chief Operating Officer position. Responsibilities of the position will be filled by a mix of existing internal resources.お知らせ • Dec 06Goodness Growth Holdings, Inc Appoints Josh Rosen to the Role of Interim PresidentGoodness Growth Holdings, Inc. announced that it has appointed Josh Rosen to the role of Interim President, effective immediately. Mr. Rosen has been serving as a director of the Company since August 2021. While he will continue to serve on the Company's board of directors, his position as Interim President will significantly expand his roles and responsibilities. Mr. Rosen's new roles and responsibilities will focus on driving operational efficiencies and adult-use preparedness in the Company's various operating markets to better align resources to capitalize on the growing adoption of adult-use regulations and managing the Company's key capital and strategic relationships. Goodness Growth's C-Suite of executives will begin reporting directly to Mr. Rosen, effective immediately. Dr. Kyle Kingsley will continue in his role as Chairman and Chief Executive Officer, with primary responsibilities focused on collaborating with Mr. Rosen on strategy, government relations and the Company's ongoing commitment to effective medical cannabis products. Mr. Rosen and Dr. Kingsley will both report directly to the Company's Board of Directors. Mr. Rosen also serves as Managing Partner at Bengal Capital, and was formerly Chief Executive Officer and Chairman of 4Front Ventures. At 4Front, Josh helped lead the transformation of a pioneering industry consulting firm into an operations-focused, multi-state operator, notably including the acquisition of Cannex Capital. Prior to 4Front, Josh gained private equity experience managing the investment portfolio for a large family office and worked extensively in the public markets as an equity analyst, primarily at the global investment bank, Credit Suisse.お知らせ • Nov 11Goodness Growth Holdings, Inc. to Report Q3, 2022 Results on Nov 14, 2022Goodness Growth Holdings, Inc. announced that they will report Q3, 2022 results After-Market on Nov 14, 2022お知らせ • Oct 15+ 1 more updateGoodness Growth Holdings, Inc., Annual General Meeting, Nov 18, 2022Goodness Growth Holdings, Inc., Annual General Meeting, Nov 18, 2022.お知らせ • Aug 26Goodness Growth Holdings, Inc. Announces Launch of Boundary Waters Pre-Rolls in MinnesotaGoodness Growth Holdings, Inc. announced the launch of its Boundary Waters line of premium cannabis pre-rolls focused on sustainability and environmental preservation. Inspired by Minnesota's Boundary Waters Canoe Area Wilderness, which exists within Superior National Forest, Boundary Waters pre-rolls are hand-rolled from premium whole flower and are available in Sativa, Indica and hybrid strains, and can be purchased in five-roll and ten-roll packs. The Company plans to donate a portion of proceeds from the sale of Boundary Waters products to help keep the Boundary Waters clean and safe. Boundary Waters pre-rolls come in sustainable packaging, made from 57% plant-based materials. The packages are recyclable and made to decompose at an accelerated rate in landfills, if not recycled. The pre-rolls themselves are made with biodegradable paper inserts. Boundary Waters pre-rolls are made from premium whole flower material and are available at launch in six strains, including Candy Glue, Chem Fruit Funk, Critical Jack, OG Kush, White Wedding and Flap Jacks. Boundary Waters pre-rolls are currently only available in Minnesota at Green Goods dispensaries operated by the Company's Minnesota subsidiary. Subject to regulatory approvals, the Company plans to expand the Boundary Waters brand to include additional product offerings and other markets.Reported Earnings • Aug 12Second quarter 2022 earnings released: US$0.048 loss per share (vs US$0.044 loss in 2Q 2021)Second quarter 2022 results: US$0.048 loss per share (down from US$0.044 loss in 2Q 2021). Revenue: US$21.1m (up 48% from 2Q 2021). Net loss: US$6.18m (loss widened 13% from 2Q 2021). Over the next year, revenue is forecast to grow 96%, compared to a 61% growth forecast for the industry in Canada. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.お知らせ • Aug 12Goodness Growth Holdings, Inc. Announces Unaudited and Condensed Impairment Results for the Quarter Ended June 30, 2022Goodness Growth Holdings, Inc. announced unaudited and condensed impairment results for the quarter ended June 30, 2022. for the quarter, the company reported Impairment of long-lived assets of $54,739,000.お知らせ • Aug 02Goodness Growth Holdings, Inc. Launches Cannabis-Infused Gummies in MinnesotaGoodness Growth Holdings, Inc. announced the addition of cannabis-infused gummies to its Vireo brand in Minnesota, in accordance with Minnesota's new regulations effective Aug. 1 allowing certified medical cannabis patients in the state to purchase certain edible products containing cannabis. The addition of edibles, including gummies with cannabis, into Minnesota's medical cannabis program offers an additional and sought-after delivery method for patients. Vireo's gummies are designed to meet the needs of a variety of cannabis patients. At launch, the gummies are available in 10mg THC formulations and in Key Lime, Concord Grape, Hawaiian Pineapple and Oxnard Strawberry flavors. An additional formulation, with equal amounts of THC and CBD and in Alfonso Mango flavor, is expected to follow. Vireo gummies are available in all eight of the Company's Green Goods® dispensaries in Minnesota. The launch of Vireo gummies in Minnesota comes after the Company's launch of edible gummies and chews under the HiColor™ brand in Maryland in late 2021, where it has since expanded to include seasonal flavors and new formulations, and the expansion of HiColor™ brand to the New York market in June 2022.お知らせ • Jun 24Goodness Growth Holdings Launches Hicolor™ Cannabis Chews in New YorkGoodness Growth Holdings, Inc. announced the launch of HiColor™ cannabis-infused chews in New York, which are now available through the Company's retail and wholesale channels in the New York market. The new line of cannabis-infused edibles is now available in five gourmet flavors and two formulations. HiColor™ chews were designed to meet the needs of a variety of cannabis consumers, with product offerings in 10 mg THC and 10:10 CBD:THC formulations. At launch, the chews are available to New York patients in Key Lime, Concord Grape, Hawaiian Pineapple, Oxnard Strawberry and Alfonso Mango flavors. The chews are vegan, gluten-free, Kosher, non-GMO and use only natural flavors. HiColor™ chews are currently available in all four of the Company's Vireo Health dispensaries in New York, as well as in select licensed dispensaries across the state with additional licensed dispensaries expected to add HiColor™ to their product assortment over the coming months. The New York launch of HiColor™ follows the brand's debut in Maryland in late 2021, where it continues to see great success and expanded flavor and formulation options, including seasonal flavors and a new formulation combining THC and CBN. Subject to regulatory approval, the Company plans to launch the HiColor™ brand in its Minnesota market later this year when the state's medical cannabis program expands to allow cannabis-infused edibles, expected to begin in August.Reported Earnings • May 13First quarter 2022 earnings released: US$0.11 loss per share (vs US$0.059 loss in 1Q 2021)First quarter 2022 results: US$0.11 loss per share (down from US$0.059 loss in 1Q 2021). Revenue: US$15.6m (up 19% from 1Q 2021). Net loss: US$14.6m (loss widened 112% from 1Q 2021). Over the next year, revenue is forecast to grow 91%, compared to a 87% growth forecast for the industry in Canada. Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.お知らせ • May 12Goodness Growth Holdings, Inc. Reports Consolidated Impairment of Long-Lived Assets for the Three Months Ended March 31, 2022Goodness Growth Holdings, Inc. reported consolidated impairment of long-lived assets for the three months ended March 31, 2022. Impairment of long-lived assets were USD 5,313,176.株主還元VREOCA PharmaceuticalsCA 市場7D-2.5%-1.4%-0.2%1Y-25.0%39.9%28.2%株主還元を見る業界別リターン: VREO過去 1 年間で39.9 % の収益を上げたCanadian Pharmaceuticals業界を下回りました。リターン対市場: VREOは、過去 1 年間で28.2 % のリターンを上げたCanadian市場を下回りました。価格変動Is VREO's price volatile compared to industry and market?VREO volatilityVREO Average Weekly Movement10.3%Pharmaceuticals Industry Average Movement10.0%Market Average Movement9.5%10% most volatile stocks in CA Market16.6%10% least volatile stocks in CA Market3.6%安定した株価: VREO 、 Canadian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: VREOの 週次ボラティリティ は、過去 1 年間で16%から10%に減少しました。会社概要設立従業員CEO（最高経営責任者ウェブサイト2004566John Mazarakisvireogrowth.comVireo Growth Inc.は、メリーランド州、ミネソタ州、ニューヨーク州で医療用および成人用大麻製品の栽培、製造、加工、販売を行う大麻会社として事業を展開している。同社は小売薬局や販売店のネットワークを通じて大麻製品を販売している。以前はグッドネス・グロース・ホールディングス社として知られていたが、2024年7月にヴィレオ・グロース社に社名変更。ヴィレオ・グロース社は2004年に法人化され、ミネソタ州ミネアポリスに本社を置いている。もっと見るVireo Growth Inc. 基礎のまとめVireo Growth の収益と売上を時価総額と比較するとどうか。VREO 基礎統計学時価総額CA$631.95m収益（TTM）-CA$114.77m売上高(TTM)CA$491.03m1.3xP/Sレシオ-5.5xPER（株価収益率VREO は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計VREO 損益計算書（TTM）収益US$350.47m売上原価US$176.47m売上総利益US$174.00mその他の費用US$255.91m収益-US$81.91m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-1.78グロス・マージン49.65%純利益率-23.37%有利子負債／自己資本比率75.9%VREO の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/17 12:22終値2026/07/17 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Vireo Growth Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Matt BottomleyCanaccord GenuityThomas KerrZacks Small-Cap ResearchSung-Chul KimZacks Small-Cap Research1 その他のアナリストを表示
お知らせ • 20mVireo Growth Inc. (CNSX:VREO) and Vive Penn, LLC acquired FarmX, LLC.Vireo Growth Inc. (CNSX:VREO) and Vive Penn, LLC entered into a Securities Purchase Agreement to acquire FarmX, LLC for $20 million on July 2, 2026. The total consideration consists of $8 million in cash payable at closing and $12 million payable through the issuance of approximately 645,161 subordinate voting shares of Vireo. The stock consideration is scheduled to be issued two years following the closing date. Post-transaction, the acquired permit will allow Vive Penn, LLC to operate up to six retail medical dispensaries in Pennsylvania. The transaction is subject to approval by regulatory board / committee and customary closing conditions. The transaction is expected to close two business days following the date the parties satisfy all conditions precedent to the agreement. Vireo Growth Inc. (CNSX:VREO) and Vive Penn, LLC completed the acquisition of FarmX, LLC on July 17, 2026.
お知らせ • Jun 17Vireo Growth Inc. (CNSX:VREO) entered into a definitive agreement to acquire C21 Investments Inc. (CNSX:CXXI) for $34.88 million.Vireo Growth Inc. (CNSX:VREO) entered into a definitive agreement to acquire C21 Investments Inc. (CNSX:CXXI) for $34.88 million on June 15, 2026. The consideration consists of 2.72 million common equity of Vireo Growth Inc. at a ratio of 0.023052 per common equity of C21 Investments Inc. As part of consideration, an undisclosed value is paid towards common equity of C21 Investments Inc. In case of termination of transaction, seller will pay a termination fee of $3 million. The transaction is subject to subject to court approval, approval by regulatory board, approval of merger agreement by target board, approval of offer by acquirer board and approval of offer by target shareholders. The Board of Directors of C21 Investments Inc. formed a special committee for the transaction. The deal has been unanimously approved by the board. The transaction is expected to close in the third quarter of 2026. Needham & Company, LLC acted as fairness opinion provider and Koffman Kalef LLP, Dorsey & Whitney LLP and DLA Piper LLP acted as legal advisors for C21 Investments Inc. Eversheds Sutherland LLP acted as legal advisor for Vireo Growth Inc.
Buy Or Sell Opportunity • Jun 04Now 232% overvalued after recent price riseOver the last 90 days, the stock has risen 2,800% to CA$17.40. The fair value is estimated to be CA$5.24, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 51% over the last 3 years. Earnings per share has grown by 40%.
お知らせ • May 26Vireo Growth Inc. (CNSX:VREO) signed a letter of intent to acquire Bridgewell Agribusiness LLC from Bwab Holdings, Llc for $40.3 million.Vireo Growth Inc. (CNSX:VREO) signed a letter of intent to acquire Bridgewell Agribusiness LLC from Bwab Holdings, Llc for $40.3 million on May 25, 2026. The consideration consists of convertible debt of Vireo Growth Inc. having a value of $10.26 million to be issued for common equity of Bridgewell Agribusiness LLC. The aggregate consideration for the Bridgewell Transaction is based on a base purchase price of US$40 million, subject to adjustments for, among other things, approximately US$30 million of assumed indebtedness of Bridgewell that will remain outstanding following closing and the assumption of certain other transaction expenses. After giving effect to such adjustments, the estimated closing purchase price is expected to be approximately US$10.26 million In exchange for the issued and outstanding membership interests of Bridgewell, Vireo will issue an unsecured, subordinated convertible note to the Seller (the “Convertible Note”) in the aggregate principal amount equal to the closing purchase price, which will automatically convert on or after the second anniversary of closing into an estimated 16,552,150 subordinate voting shares of Vireo (the “Consideration Shares”) at a deemed price of US$0.62 per Consideration Share (which final price will be subject to the policies of the Canadian Securities Exchange and based on the volume weighted average trading price of the Company’s subordinate voting shares for 20 consecutive trading days ending two trading days prior to the closing date). The aggregate principal amount of the Convertible Note and number of Consideration Shares issuable thereunder are subject to certain post-closing purchase price and other adjustments. The transaction is subject to approval by regulatory board / committee and definitive agreement. The Bridgewell Transaction could close any time following five (5) business days.
Reported Earnings • May 13First quarter 2026 earnings released: US$0.019 loss per share (vs US$0.018 loss in 1Q 2025)First quarter 2026 results: US$0.019 loss per share (further deteriorated from US$0.018 loss in 1Q 2025). Revenue: US$106.2m (up 333% from 1Q 2025). Net loss: US$20.3m (loss widened 212% from 1Q 2025). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 33% per year, which means it is significantly lagging earnings growth.
お知らせ • May 07Vireo Growth Inc. to Report Q1, 2026 Results on May 12, 2026Vireo Growth Inc. announced that they will report Q1, 2026 results Pre-Market on May 12, 2026
お知らせ • 20mVireo Growth Inc. (CNSX:VREO) and Vive Penn, LLC acquired FarmX, LLC.Vireo Growth Inc. (CNSX:VREO) and Vive Penn, LLC entered into a Securities Purchase Agreement to acquire FarmX, LLC for $20 million on July 2, 2026. The total consideration consists of $8 million in cash payable at closing and $12 million payable through the issuance of approximately 645,161 subordinate voting shares of Vireo. The stock consideration is scheduled to be issued two years following the closing date. Post-transaction, the acquired permit will allow Vive Penn, LLC to operate up to six retail medical dispensaries in Pennsylvania. The transaction is subject to approval by regulatory board / committee and customary closing conditions. The transaction is expected to close two business days following the date the parties satisfy all conditions precedent to the agreement. Vireo Growth Inc. (CNSX:VREO) and Vive Penn, LLC completed the acquisition of FarmX, LLC on July 17, 2026.
お知らせ • Jun 17Vireo Growth Inc. (CNSX:VREO) entered into a definitive agreement to acquire C21 Investments Inc. (CNSX:CXXI) for $34.88 million.Vireo Growth Inc. (CNSX:VREO) entered into a definitive agreement to acquire C21 Investments Inc. (CNSX:CXXI) for $34.88 million on June 15, 2026. The consideration consists of 2.72 million common equity of Vireo Growth Inc. at a ratio of 0.023052 per common equity of C21 Investments Inc. As part of consideration, an undisclosed value is paid towards common equity of C21 Investments Inc. In case of termination of transaction, seller will pay a termination fee of $3 million. The transaction is subject to subject to court approval, approval by regulatory board, approval of merger agreement by target board, approval of offer by acquirer board and approval of offer by target shareholders. The Board of Directors of C21 Investments Inc. formed a special committee for the transaction. The deal has been unanimously approved by the board. The transaction is expected to close in the third quarter of 2026. Needham & Company, LLC acted as fairness opinion provider and Koffman Kalef LLP, Dorsey & Whitney LLP and DLA Piper LLP acted as legal advisors for C21 Investments Inc. Eversheds Sutherland LLP acted as legal advisor for Vireo Growth Inc.
Buy Or Sell Opportunity • Jun 04Now 232% overvalued after recent price riseOver the last 90 days, the stock has risen 2,800% to CA$17.40. The fair value is estimated to be CA$5.24, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 51% over the last 3 years. Earnings per share has grown by 40%.
お知らせ • May 26Vireo Growth Inc. (CNSX:VREO) signed a letter of intent to acquire Bridgewell Agribusiness LLC from Bwab Holdings, Llc for $40.3 million.Vireo Growth Inc. (CNSX:VREO) signed a letter of intent to acquire Bridgewell Agribusiness LLC from Bwab Holdings, Llc for $40.3 million on May 25, 2026. The consideration consists of convertible debt of Vireo Growth Inc. having a value of $10.26 million to be issued for common equity of Bridgewell Agribusiness LLC. The aggregate consideration for the Bridgewell Transaction is based on a base purchase price of US$40 million, subject to adjustments for, among other things, approximately US$30 million of assumed indebtedness of Bridgewell that will remain outstanding following closing and the assumption of certain other transaction expenses. After giving effect to such adjustments, the estimated closing purchase price is expected to be approximately US$10.26 million In exchange for the issued and outstanding membership interests of Bridgewell, Vireo will issue an unsecured, subordinated convertible note to the Seller (the “Convertible Note”) in the aggregate principal amount equal to the closing purchase price, which will automatically convert on or after the second anniversary of closing into an estimated 16,552,150 subordinate voting shares of Vireo (the “Consideration Shares”) at a deemed price of US$0.62 per Consideration Share (which final price will be subject to the policies of the Canadian Securities Exchange and based on the volume weighted average trading price of the Company’s subordinate voting shares for 20 consecutive trading days ending two trading days prior to the closing date). The aggregate principal amount of the Convertible Note and number of Consideration Shares issuable thereunder are subject to certain post-closing purchase price and other adjustments. The transaction is subject to approval by regulatory board / committee and definitive agreement. The Bridgewell Transaction could close any time following five (5) business days.
Reported Earnings • May 13First quarter 2026 earnings released: US$0.019 loss per share (vs US$0.018 loss in 1Q 2025)First quarter 2026 results: US$0.019 loss per share (further deteriorated from US$0.018 loss in 1Q 2025). Revenue: US$106.2m (up 333% from 1Q 2025). Net loss: US$20.3m (loss widened 212% from 1Q 2025). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 33% per year, which means it is significantly lagging earnings growth.
お知らせ • May 07Vireo Growth Inc. to Report Q1, 2026 Results on May 12, 2026Vireo Growth Inc. announced that they will report Q1, 2026 results Pre-Market on May 12, 2026
お知らせ • May 02Vireo Growth Inc. (CNSX:VREO) entered into a definitive arrangement agreement to acquire FLUENT Corp. (CNSX:FNT.U) for $19.2 million.Vireo Growth Inc. (CNSX:VREO) entered into a definitive arrangement agreement to acquire FLUENT Corp. (CNSX:FNT.U) for $19.2 million on April 30, 2026. As part of the acquisition, Vireo Growth Inc. will acquire all of the issued and outstanding common shares of FLUENT Corp. As part of consideration, each shareholder of FLUENT Corp will receive 0.0705359 of a subordinate voting share of Vireo Growth Inc in exchange for each FLUENT Corp Share held. Following the completion of the Transaction, FLUENT will join the Vireo ecosystem and gain exposure to a larger and well capitalized multi-state operator currently operating in 10 states across the U.S. In connection with the Transaction, Vireo has entered into voting support agreements with certain directors, officers and key shareholders of FLUENT, with such holders representing approximately 38.3% of the issued and outstanding FLUENT Shares, pursuant to which they have agreed to, among other things, vote their FLUENT Shares in favor of the Transaction. Chris Hagedorn has resigned from the FLUENT Board. The vacancy will not be filled at this time. Upon completion, it is expected that the FLUENT Shares will be delisted from the Canadian Securities Exchange (“CSE”) and the OTCQB Venture Market and that FLUENT will apply to cease to be a reporting issuer under applicable Canadian securities laws. In case of termination of transaction, FLUENT Corp. will pay a termination fee of $2 million to Vireo Growth Inc. The transaction is subject to court approvals, as well as the receipt of all required regulatory approvals, the completion of the Equitization, and the satisfaction of certain other closing conditions customary in transactions of this nature, approval by the shareholders of FLUENT Corp and other third-party approvals. The Board of Directors of FLUENT Corp. formed a special committee for the transaction. The Special Committee and the FLUENT Board have unanimously determined that the Transaction is in the best interests of FLUENT and is fair to the FLUENT Shareholders and the FLUENT Board recommends that the FLUENT Shareholders vote in favor of the Transaction. The transaction is expected to close in the fourth quarter of 2026. ATB Cormark Capital Markets acted as fairness opinion provider to the Special Committee and board of directors of FLUENT Corp. ATB Cormark Capital Markets acted as financial advisor to the Special Committee of FLUENT Corp. Cassels Brock & Blackwell LLP acted as legal advisor to FLUENT Corp. Goodwin Procter LLP acted as legal advisor to FLUENT Corp. DLA Piper (Canada) LLP acted as legal advisor to Vireo Growth Inc. Eversheds Sutherland (US) LLP acted as legal advisor to Vireo Growth Inc. Shenker Russo & Clark LLP acted as legal advisor to Vireo Growth Inc. Foley & Lardner LLP acted as legal advisor to Vireo Growth Inc.
お知らせ • Apr 17Vireo Growth Inc. announced that it has received $50.612571 million in fundingOn April 16, 2026. Vireo Growth Inc. announced that it has closed the transaction.
お知らせ • Apr 09Vireo Growth Inc. (CNSX : VREO) completed the acquisition of The Hawthorne Gardening Company from Smg Growing Media, Inc. for 84.6 million.Vireo Growth Inc. (CNSX : VREO) entered into a nonbinding memorandum of understanding to acquire The Hawthorne Gardening Company from Smg Growing Media, Inc. for approximately $120 million on January 15, 2026. As part of consideration Vireo Growth Inc. issued 206 million ordinary shares, a warrant to purchase 80 million at an exercise price of $0.85 per Share, exercisable for a period of five years from the date of issuance. Additional Vireo Growth Inc. acquire The Hawthorne Gardening Company $35 million of cash, approximately $50 million of net working capital, and would be provided approximately $20 million of inventory. Vireo intends to name Chris Hagedorn, Executive Vice President of ScottsMiracle-Gro and Executive Lead of the Hawthorne business, to its Board of Directors upon completion of the transition upon completion of the transaction and shareholder approval. The transaction is subjected to regulatory approvals and the finalization of a definitive agreement. If applicable, the approval of the Canadian Securities Exchange. The expected to be completed during the second quarter of 2026. Vireo Growth Inc. (CNSX : VREO) completed the acquisition of The Hawthorne Gardening Company from Smg Growing Media, Inc. for 84.6 million on April 8, 2026. Under the terms of the transaction, Vireo Growth Inc. acquired $35 million of cash held by Hawthorne, and issued 213 million of its subordinate voting shares and a warrant to purchase 80 million at an exercise price of $0.85 per Share.
お知らせ • Apr 01Vireo Growth Inc. Announces Cory Azzalino to Step into the CEO Role of Vireo’s California BusinessVireo Growth Inc. announced Cory Azzalino will step into the CEO role of Vireo’s California business – Cory and his team bring operational acumen and emphasis on retail excellence which strengthens Vireo’s platform.
Reported Earnings • Mar 18Full year 2025 earnings released: US$0.093 loss per share (vs US$0.15 loss in FY 2024)Full year 2025 results: US$0.093 loss per share. Revenue: US$268.8m (up 170% from FY 2024). Net loss: US$68.1m (loss widened 143% from FY 2024). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 10.0% growth forecast for the Pharmaceuticals industry in Canada.
お知らせ • Mar 17Vireo Growth Inc., Annual General Meeting, May 29, 2026Vireo Growth Inc., Annual General Meeting, May 29, 2026.
お知らせ • Mar 10Vireo Growth Inc. to Report Q4, 2025 Results on Mar 17, 2026Vireo Growth Inc. announced that they will report Q4, 2025 results Pre-Market on Mar 17, 2026
お知らせ • Jan 28Vireo Growth Inc. (CNSX : VREO) entered into a nonbinding Memorandum of Understanding to acquire The Hawthorne Gardening Company from Smg Growing Media, Inc.Vireo Growth Inc. (CNSX : VREO) entered into a nonbinding memorandum of understanding to acquire The Hawthorne Gardening Company from Smg Growing Media, Inc. on January 28, 2026. Upon completion, Vireo intends to name Chris Hagedorn, Executive Vice President of ScottsMiracle-Gro and Executive Lead of the Hawthorne business, to its Board of Directors.
Recent Insider Transactions Derivative • Jan 02President exercised options and sold CA$104k worth of stockOn the 29th of December, Amber Shimpa exercised options to acquire 127k shares at no cost and sold these for an average price of CA$0.82 per share. This trade did not impact their existing holding. Since March 2025, Amber's direct individual holding has increased from 875.63k shares to 1.97m. This was the only transaction from an insider over the last 12 months.
分析記事 • Dec 30Vireo Growth Inc.'s (CSE:VREO) 38% Jump Shows Its Popularity With InvestorsVireo Growth Inc. ( CSE:VREO ) shareholders are no doubt pleased to see that the share price has bounced 38% in the...
お知らせ • Dec 23Vireo Growth Inc. (CNSX:VREO) agreed to acquire Eaze Technologies, Inc. for $48.9 million.Vireo Growth Inc. (CNSX:VREO) agreed to acquire Eaze Technologies, Inc. for $48.9 million on December 22, 2025. The consideration is payable through the issuance of approximately 84 million subordinate voting shares of the Vireo at closing. Total consideration payable in the transaction will be subject to adjustment based on closing levels of cash, indebtedness, tax obligations and working capital adjustments, as well as the occurrence of certain other events by the closing date. Eaze may be entitled to earn-out consideration as of December 31, 2026. Eaze will become a wholly-owned subsidiary of Vireo. The expected completion of the transaction is January 1, 2026 to June 30, 2026.
お知らせ • Dec 18Vireo Growth Inc. (CNSX:VREO) entered into an asset purchase agreement to acquire Certain retail assets and properties of PharmaCann Inc. for $49 million.Vireo Growth Inc. (CNSX:VREO) entered into an asset purchase agreement to acquire Certain retail assets and properties of PharmaCann Inc. for $49 million on December 16, 2025. Total consideration is payable in subordinate voting shares of the Vireo Growth, as well as the assumption of certain liabilities. The transaction is subject to satisfaction of closing conditions and state and local regulatory approvals. The transaction is expected to close during the first half of calendar year 2026.
分析記事 • Nov 15With A 35% Price Drop For Vireo Growth Inc. (CSE:VREO) You'll Still Get What You Pay ForThe Vireo Growth Inc. ( CSE:VREO ) share price has fared very poorly over the last month, falling by a substantial 35...
New Risk • Nov 14New major risk - Revenue and earnings growthEarnings have declined by 1.2% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 1.2% per year over the past 5 years. Shareholders have been substantially diluted in the past year (362% increase in shares outstanding).
Reported Earnings • Nov 14Third quarter 2025 earnings released: US$0.042 loss per share (vs US$0.024 loss in 3Q 2024)Third quarter 2025 results: US$0.042 loss per share (further deteriorated from US$0.024 loss in 3Q 2024). Revenue: US$91.7m (up 264% from 3Q 2024). Net loss: US$26.3m (loss widened 434% from 3Q 2024). Revenue is forecast to grow 66% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.
お知らせ • Oct 31Vireo Growth Inc. to Report Q3, 2025 Results on Nov 12, 2025Vireo Growth Inc. announced that they will report Q3, 2025 results After-Market on Nov 12, 2025
お知らせ • Oct 29Vireo Growth Inc. and Verano Holdings Corp. Reaches Comprehensive Settlement Dismissing All Outstanding Litigation MattersVireo Growth Inc. and Verano Holdings Corp. on October 29, 2025 announced that they have reached a comprehensive settlement dismissing all outstanding litigation matters between the two Companies that are pending before the Supreme Court of British Columbia, Canada. The terms of the Settlement Agreement were approved by the respective Boards of Directors of both Companies. The value of the settlement to Vireo is approximately USD 10 million consisting of the acquisition of certain real estate assets and USD 1 million in cash. The resolution marks the conclusion of a complex legal chapter and reflects a commitment by both Companies to move forward in a constructive manner. Both Companies reiterated their dedication to delivering long-term value to their shareholders and quality products and services to their customers.
お知らせ • Oct 24Vireo Growth Inc. announced that it has received $61.996221 million in fundingOn October 23, 2025, Vireo Growth Inc closed the transaction. The transaction included participation from 22 investors.
お知らせ • Sep 16Vireo Growth Inc. Announces Launch of Adult-Use Cannabis Sales in MinnesotaVireo Growth Inc. announced that on September 16, 2025, it recorded its first sale of adult use cannabis in Minnesota at its historic downtown Minneapolis Green Goods® dispensary. The Company is now dispensing a full suite of both medical and adult-use cannabis products at all eight of its Green Goods™ dispensaries located throughout the State of Minnesota. Vireo has been operating in Minnesota’s medical cannabis market since 2014, serving tens of thousands of patients with safe, reliable products. The Company is committed to expanding access, improving product quality, and supporting the state’s transition to a sustainable, locally driven adult-use market. As one of the state’s operational licensed adult-use cannabis cultivators and retailers, and a population of 5.7 million people, the launch of Minnesota’s adult-use cannabis market is expected to serve as a strong organic revenue growth catalyst for Vireo for the foreseeable future. Green Goods® offers a full suite of medical and adult-use cannabis products and form factors including flower, pre-rolls, edibles, and beverages, and currently operates eight retail dispensaries in Minnesota. Green Goods® dispensaries are located in Minneapolis, Blaine, Bloomington, Burnsville, Duluth, Moorhead, Rochester, and Woodbury. For more information about Green Goods or to shop its product menu, please visit www.visitgreengoods.com.
分析記事 • Sep 11With A 33% Price Drop For Vireo Growth Inc. (CSE:VREO) You'll Still Get What You Pay ForVireo Growth Inc. ( CSE:VREO ) shares have retraced a considerable 33% in the last month, reversing a fair amount of...
Reported Earnings • Aug 14Second quarter 2025 earnings released: US$0.027 loss per share (vs US$0.005 loss in 2Q 2024)Second quarter 2025 results: US$0.027 loss per share (further deteriorated from US$0.005 loss in 2Q 2024). Revenue: US$48.1m (up 91% from 2Q 2024). Net loss: US$14.9m (loss widened US$14.3m from 2Q 2024). Revenue is forecast to grow 78% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
お知らせ • Aug 05Vireo Growth Inc. to Report Q2, 2025 Results on Aug 13, 2025Vireo Growth Inc. announced that they will report Q2, 2025 results Pre-Market on Aug 13, 2025
お知らせ • Jul 10Vireo Growth Inc. announced that it has received $10 million in funding from Chicago Atlantic Opportunity Finance, LLCVireo Growth Inc announced that it has completed a private placement and issued $10,000,000 principal amount of convertible Notes on July 9, 2025. The Notes are convertible into an aggregate of 16,000,000 Shares upon exercise. The new convertible note was issued in reliance upon exemptions from the registration requirements of the U.S. Securities Act of 1933, as amended and applicable Canadian and U.S state Securities laws. The transaction included participation from Chicago Atlantic Opportunity Finance, LLC.
お知らせ • Jun 10Vireo Growth Inc. (CNSX:VREO) completed the acquisition of Deep Roots Harvest, Inc. for $64.14 million.Vireo Growth Inc. (CNSX:VREO) has signed definitive agreement to acquire Deep Roots Harvest, Inc. on December 18, 2024. Total consideration is approximately $397 million of all-stock transactions. In Related transactions Vireo has signed definitive agreements to acquire Proper Brands in Missouri and WholesomeCo Cannabis in Utah, while also signing a binding MOU to acquire The Flowery in Florida. Vireo estimates proforma revenue and EBITDA of the combined company of approximately $394 million and $94 million, respectively, for calendar year 2024. Upon closing of the Merger Transactions, Vireo estimates the combined company will be well-positioned for further growth with a favorable balance sheet consisting of approximately $99 million of cash and $78 million of net debt with an EBITDA leverage ratio of approximately 0.8x. The Proper Brands, Deep Roots Harvest and WholesomeCo Cannabis are expected to be acquired at a multiple of 4.175x 2024 “Reference EBITDA” pro-forma for pending acquisitions as well as planned new retail openings and expansion projects. Each transaction has been based on a $0.52 Vireo share reference price. The Deep Roots Merger Agreement also contains customary indemnification obligations of Vireo and Deep Roots, other obligations of the parties and termination provisions, under which, subject to certain conditions and in certain instances of termination, would require Vireo or Deep Roots to pay a termination fee equal to $6.37624 million. These acquisition targets may qualify for earnout payments on December 31, 2026, based on 4x EBITDA growth compared to Reference EBITDA, adjusted for incremental debt, and paid out using a share price at the higher of $1.05 or 20-day VWAP as of December 31, 2026. Reference EBITDA for Proper Brands, Deep Roots Harvest and WholesomeCo Cannabis are $31.0 million, $31.0 million, and $16.0 million, respectively. John Mazarakis, co-founder at Chicago Atlantic, has been appointed to the role of Chief Executive Officer and Co-Executive Chairman, effective immediately. Tyson Macdonald, former partner at TrueRise Capital, has been appointed to the role of Chief Financial Officer, effective immediately. Amber Shimpa will continue to serve as President of the Company and as Chief Executive Officer of Minnesota, Maryland, and New York. Implementation of the Merger Transactions are subject to the approval of holders of a majority of Vireo's voting shares and regulatory approvals. The Merger Transactions have been unanimously approved by the Boards of Directors of Vireo and each of the target acquisition companies. Vireo anticipates that closing of all of the Merger Transactions to take at least six months pending shareholder and regulatory approvals. Vireo expects that each transaction will be accretive to the broader portfolio. Moelis & Company LLC acted as fairness opinion provider for Boards of Directors of Vireo Growth Inc. Moelis & Company LLC acted as financial advisor for Vireo Growth Inc. Dorsey & Whitney LLP acted as legal advisor for Vireo Growth Inc. Vireo Growth Inc. (CNSX:VREO) completed the acquisition of Deep Roots Harvest, Inc. for $64.14 million on June 9, 2025. Total consideration for the transaction is paid in the form of 255.2 million Subordinate Voting Shares of Vireo at a reference price per share of $0.52. The purchase price of the Deep Roots transaction represents a multiple of 4.175x 2024 “Closing EBITDA” of $30 million.
お知らせ • Jun 06Vireo Growth Inc. (CNSX:VREO) completed the acquisition of Proper Brands for $73.3 million.Vireo Growth Inc. (CNSX:VREO) entered into a definitive agreement to acquire Proper Brands on December 18, 2024. Under the terms of the transaction, the transaction is expected to be effected by way of an all-stock transaction, and The Proper Brands, Deep Roots Harvest and WholesomeCo Cannabis are expected to be acquired at a multiple of 4.175x 2024 “Reference EBITDA” pro-forma for pending acquisitions as well as planned new retail openings and expansion projects. Each transaction has been based on a $0.52 Vireo share reference price. Reference EBITDA for Proper Brands is $31.0 million. Vireo will include in the stock merger consideration calculation an amount equal to $2,139,200 for the stockholders of Proper Brands for all of the outstanding equity interests in Arches IP, Inc. owned by Proper Brands with a potential for earnout payments based on performance through December 31, 2026, based on the greater of $37.5 million or 5x revenue measured at the higher of trailing-twelve-month or nine-month annualized net revenues, paid out using a share price at the higher of $1.05 or 20-day VWAP as of December 31, 2026. The seller of Proper Brand has agreed to voluntary share lock-up after 33 months of consummation. In separate transactions, Vireo will also acquire Deep Roots Harvest, WholesomeCo Cannabis, and The Flowery. The transaction is subject to approval by regulatory board, approval of merger agreement by target board, approval of offer by acquirer board, subject to shareholder approval and lock-up agreement, and a clawback provision if they perform below the respective Reference EBITDA measured as the higher of trailing twelve-months or nine-months annualized EBITDA as of December 31, 2026, adjusted for any intercompany funding. The Merger Transactions have been unanimously approved by the Boards of Directors of Vireo and Proper Brands. In certain instances of termination, Vireo or Proper Brands is required to pay a termination fee equal to $4,631,012. Moelis & Company LLC acted as financial advisor and Fairness Opinion Provider, and Nicole Stanton of Dorsey & Whitney LLP acted as legal advisor to Vireo. Lineage Merchant Partners, LLC acted as placement agent for the financing. Vireo Growth Inc. (CNSX:VREO) completed the acquisition of Proper Brands for $73.3 million on June 5, 2025. Total consideration for the transactions was $102 million, paid in the form of 196.2 million Subordinate Voting Shares of Vireo at a reference price per share of $0.52.
お知らせ • May 13Vireo Growth Inc. (CNSX:VREO) completed the acquisition of WholesomeCo Cannabis.Vireo Growth Inc. (CNSX:VREO) signed an agreement to acquire WholesomeCo Cannabis on December 18, 2024. Vireo has signed three definitive documents and one binding Memorandum of Understanding to acquire four single-state operators (Proper Brands, Deep Roots Harvest, and Bill’s Nursery, Inc, WholesomeCo Cannabis) for total consideration of approximately $397 million in a series of all-stock transactions and may qualify for earnout payments on December 31, 2026. Vireo will include in the stock merger consideration calculation an amount equal to $11,860,800 for the stockholders of WholesomeCo Cannabis for all of the outstanding equity interests in Arches IP, Inc. owned by WholesomeCo Cannabis with a potential for earnout payments based on performance through December 31, 2026, based on the greater of $37.5 million or 5x revenue measured at the higher of trailing-twelve-month or nine-month annualized net revenues, paid out using a share price at the higher of $1.05 or 20-day VWAP as of December 31, 2026. The transaction is subject to certain shareholder and regulatory approvals, and clawback provision. In certain instances of termination, Vireo or WholesomeCo Cannabis is required to pay a termination fee equal to $3,394,217. The Merger Transactions have been unanimously approved by the Boards of Directors of Vireo and WholesomeCo Cannabis. As of March 9, 2025, Vireo Growth Inc. has obtained required regulatory approvals and is working toward satisfying all other customary closing conditions, which it expects to meet during the second quarter of 2025. Moelis & Company LLC acted as financial advisor and fairness opinion provider, and Nicole Stanton of Dorsey & Whitney LLP acted as legal advisor to Vireo. Lineage Merchant Partners, LLC acted as placement agent for the financing. Adam Hull of Polsinelli PC acted as legal advisor to WholesomeCo. Vireo Growth Inc. (CNSX:VREO) completed the acquisition of WholesomeCo Cannabis for $69.8 million on May 12, 2025. $69.8 million paid in the form of 134.2 million Subordinate Voting Shares of Vireo at a reference price per share of $0.52.
Reported Earnings • May 10First quarter 2025 earnings released: US$0.018 loss per share (vs US$0.047 loss in 1Q 2024)First quarter 2025 results: US$0.018 loss per share (improved from US$0.047 loss in 1Q 2024). Revenue: US$24.5m (up 1.9% from 1Q 2024). Net loss: US$6.51m (loss narrowed 3.0% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.
お知らせ • Apr 29Vireo Growth Inc. to Report Q1, 2025 Results on May 09, 2025Vireo Growth Inc. announced that they will report Q1, 2025 results Pre-Market on May 09, 2025
お知らせ • Apr 09Vireo Growth Inc., Annual General Meeting, Jun 20, 2025Vireo Growth Inc., Annual General Meeting, Jun 20, 2025.
分析記事 • Apr 04Revenues Not Telling The Story For Vireo Growth Inc. (CSE:VREO) After Shares Rise 26%Vireo Growth Inc. ( CSE:VREO ) shareholders are no doubt pleased to see that the share price has bounced 26% in the...
分析記事 • Mar 31Is Vireo Growth (CSE:VREO) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Reported Earnings • Mar 04Full year 2024 earnings released: US$0.15 loss per share (vs US$0.19 loss in FY 2023)Full year 2024 results: US$0.15 loss per share. Revenue: US$99.4m (up 13% from FY 2023). Net loss: US$28.0m (loss widened 9.6% from FY 2023). Revenue is forecast to grow 8.1% p.a. on average during the next 2 years, compared to a 7.9% growth forecast for the Pharmaceuticals industry in Canada.
お知らせ • Feb 20Vireo Growth Inc. to Report Q4, 2024 Results on Mar 04, 2025Vireo Growth Inc. announced that they will report Q4, 2024 results Pre-Market on Mar 04, 2025
お知らせ • Jan 01Vireo Growth Inc. announced that it has received $80.960546 million in fundingOn December 30, 2024, Vireo Growth Inc., closed the transaction. The company issued 129,536,874 subordinate voting shares at a price of $0.625 per share for the gross proceeds of $80,960,546.25 in the transaction. The transaction has been oversubscribed.
お知らせ • Dec 19+ 4 more updatesVireo Growth Inc. (CNSX:VREO) entered into a definitive agreement to acquire Proper Brands.Vireo Growth Inc. (CNSX:VREO) entered into a definitive agreement to acquire Proper Brands on December 18, 2024. Under the terms of the transaction, the transaction is expected to be effected by way of an all-stock transaction, and The Proper Brands, Deep Roots Harvest and WholesomeCo Cannabis are expected to be acquired at a multiple of 4.175x 2024 “Reference EBITDA” pro-forma for pending acquisitions as well as planned new retail openings and expansion projects. Each transaction has been based on a $0.52 Vireo share reference price. These acquisition targets may qualify for earnout payments on December 31, 2026, based on 4x EBITDA growth compared to Reference EBITDA, adjusted for incremental debt, and paid out using a share price at the higher of $1.05 or 20-day VWAP as of December 31, 2026. Reference EBITDA for Proper Brands is$31.0 million. Total payment for Arches includes $14 million in upfront consideration to WholesomeCo and Proper Brands with a potential for earnout payments based on performance through December 31, 2026, based on the greater of $37.5 million or 5x revenue measured at the higher of trailing-twelve-month or nine-month annualized net revenues, paid out using a share price at the higher of $1.05 or 20-day VWAP as of December 31, 2026. The seller of Bill's Nursery has agreed to voluntary share lock-up after 33 months of consummation. In separate transactions, Vireo will also acquire Deep Roots Harvest, WholesomeCo Cannabis, and The Flowery. The transaction is subject to approval by regulatory board, approval of merger agreement by target board, approval of offer by acquirer board, subject to shareholder approval and lock-up agreement, and a clawback provision if they perform below the respective Reference EBITDA measured as the higher of trailing twelve-months or nine-months annualized EBITDA as of December 31, 2026, adjusted for any intercompany funding. The Merger Transactions have been unanimously approved by the Boards of Directors of Vireo and Bill's Nursery. Moelis & Company LLC acted as financial advisor and Fairness Opinion Provider, and Dorsey & Whitney LLP acted as legal advisor to Vireo. Lineage Merchant Partners, LLC acted as placement agent for the financing.
分析記事 • Nov 27Risks Still Elevated At These Prices As Vireo Growth Inc. (CSE:VREO) Shares Dive 26%Vireo Growth Inc. ( CSE:VREO ) shareholders that were waiting for something to happen have been dealt a blow with a 26...
Reported Earnings • Nov 15Third quarter 2024 earnings released: US$0.024 loss per share (vs US$0.037 loss in 3Q 2023)Third quarter 2024 results: US$0.024 loss per share (improved from US$0.037 loss in 3Q 2023). Revenue: US$25.2m (up 2.0% from 3Q 2023). Net loss: US$4.93m (loss narrowed 5.8% from 3Q 2023). Revenue is forecast to grow 3.4% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings.
お知らせ • Nov 05Vireo Growth Inc. announced that it expects to receive $10 million in fundingVireo Growth Inc. announced that it has secured a new convertible debt facility which provides a financing commitment of up to $10,000,000 in aggregate principal amount of convertible notes on November 4, 2024. This facility is being funded by the Company’s senior secured lender and its affiliates under the Company’s existing credit agreement. The convertible facility has a term of three years, with a cash interest rate of 12.0 percent, and such interest shall be paid to Lender in cash on the last business day of each calendar month. The Convertible Notes shall be convertible at any time into Subordinate Voting Shares of the Company, at the option of Lender, in whole but not in part, in a single transaction, at a conversion price equal to $0.625.
お知らせ • Oct 30Vireo Growth Inc. to Report Q3, 2024 Results on Nov 13, 2024Vireo Growth Inc. announced that they will report Q3, 2024 results After-Market on Nov 13, 2024
New Risk • Oct 13New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: CA$110.5m (US$80.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$23m). Shareholders have been substantially diluted in the past year (61% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (17% average weekly change). Market cap is less than US$100m (CA$110.5m market cap, or US$80.3m).
分析記事 • Oct 12Vireo Growth Inc.'s (CSE:VREO) 29% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatioVireo Growth Inc. ( CSE:VREO ) shares have had a horrible month, losing 29% after a relatively good period beforehand...
お知らせ • Oct 11+ 1 more updateVireo Growth Inc. Announces CFO ChangesVireo Growth Inc. announced several leadership updates. Josh Rosen has resigned from the Company's interim Chief Financial Officer, effective immediately, to focus on his other business ventures. Mr. Rosen was first elected to the Board in August 2021, and appointed to executive leadership roles in November 2022, including, most recently, the roles of Chief Executive Officer and interim Chief Financial Officer. The Company has engaged Mr. Rosen going forward with a consulting agreement. Joe Duxbury has been appointed as Interim Chief Financial Officer while the Company searches for a permanent replacement. Mr. Duxbury has been with the Company since 2019 in financial and accounting roles of increasing responsibility, and most recently was serving as Vice President of Finance leading external reporting and investor relations.
お知らせ • Oct 10Vireo Growth Inc. Announces Resignation of Josh Rosen as DirectorVireo Growth Inc. announced several leadership updates. Josh Rosen has resigned from the Company's Board of Directors, effective immediately, to focus on his other business ventures. Mr. Rosen was first elected to the Board in August 2021, and appointed to executive leadership roles in November 2022, including, most recently, the roles of Chief Executive Officer and interim Chief Financial Officer. The Company has engaged Mr. Rosen going forward with a consulting agreement.
Board Change • Sep 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. CEO, Interim CFO & Director Josh Rosen was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
New Risk • Aug 21New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 61% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-US$23m). Shareholders have been substantially diluted in the past year (61% increase in shares outstanding). Minor Risk Share price has been volatile over the past 3 months (15% average weekly change).
お知らせ • Aug 20Vireo Growth Inc. announced that it has received $5.3875 million in fundingOn August 20, 2024, Vireo Growth Inc. closed the transaction. The transaction included participation from 14 investors.
分析記事 • Aug 10Vireo Growth Inc. (CSE:VREO) Stock Rockets 25% As Investors Are Less Pessimistic Than ExpectedVireo Growth Inc. ( CSE:VREO ) shares have had a really impressive month, gaining 25% after a shaky period beforehand...
Reported Earnings • Aug 07Second quarter 2024 earnings released: US$0.005 loss per share (vs US$0.057 loss in 2Q 2023)Second quarter 2024 results: US$0.005 loss per share (improved from US$0.057 loss in 2Q 2023). Revenue: US$25.1m (up 24% from 2Q 2023). Net loss: US$668.4k (loss narrowed 91% from 2Q 2023). Revenue is expected to decline by 1.4% p.a. on average during the next 2 years, while revenues in the Pharmaceuticals industry in Canada are expected to grow by 11%. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings.
お知らせ • Jul 23Vireo Growth Inc. to Report Q2, 2024 Results on Aug 06, 2024Vireo Growth Inc. announced that they will report Q2, 2024 results After-Market on Aug 06, 2024
分析記事 • Jun 01Market Might Still Lack Some Conviction On Goodness Growth Holdings, Inc. (CSE:GDNS) Even After 30% Share Price BoostGoodness Growth Holdings, Inc. ( CSE:GDNS ) shares have continued their recent momentum with a 30% gain in the last...
お知らせ • May 31Goodness Growth Holdings, Inc. announced that it expects to receive $0.7 million in fundingGoodness Growth Holdings, Inc. announced a non-brokered private placement of its subordinate voting shares for the gross proceeds of $700,000 on May 30, 2024. The company expects that this transaction will be completed within the next five business days. All of the subordinate voting shares issued in connection with this private placement will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation.
Reported Earnings • May 08First quarter 2024 earnings released: US$0.047 loss per share (vs US$0.066 loss in 1Q 2023)First quarter 2024 results: US$0.047 loss per share (improved from US$0.066 loss in 1Q 2023). Revenue: US$24.1m (up 26% from 1Q 2023). Net loss: US$6.71m (loss narrowed 20% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 34% per year, which means it is performing significantly worse than earnings.
お知らせ • May 03+ 1 more updateGoodness Growth Holdings, Inc. Appoints Josh Rosen as Chief Executive OfficerGoodness Growth Holdings, Inc. announced several leadership and corporate updates related to the day-to-day management of its business. Josh Rosen, who has served as Interim CEO since February of 2023, has been appointed as Chief Executive Officer, effective immediately. Josh Rosen’s leadership over the course of the past 14 months has been instrumental in securing a path forward for Company as a standalone enterprise. The company have been immensely impressed with Josh’s stewardship of the organization through the exceptionally challenging circumstances that were created by Verano’s wrongful termination of merger agreement. During his tenure as Interim CEO, he has significantly improved fundamental operating and financial performance, and has represented the Company admirably in his interactions with both internal and external stakeholders.
お知らせ • May 01Goodness Growth Holdings, Inc. to Report Q1, 2024 Results on May 07, 2024Goodness Growth Holdings, Inc. announced that they will report Q1, 2024 results After-Market on May 07, 2024
お知らせ • Apr 13Goodness Growth Holdings, Inc., Annual General Meeting, Jun 21, 2024Goodness Growth Holdings, Inc., Annual General Meeting, Jun 21, 2024.
分析記事 • Apr 06Goodness Growth Holdings, Inc. (CSE:GDNS) Stock Rockets 30% But Many Are Still Ignoring The CompanyDespite an already strong run, Goodness Growth Holdings, Inc. ( CSE:GDNS ) shares have been powering on, with a gain of...
お知らせ • Apr 03Goodness Growth Holdings, Inc. Reports Impairment Charges for the Fourth Quarter Ended December 31, 2023Goodness Growth Holdings, Inc. reported impairment charges for the fourth quarter ended December 31, 2023. For the period, the company reported loss on impairment of long-lived assets of USD 411,629 compared to USD 1,119,583 last year same period.
Reported Earnings • Apr 02Full year 2023 earnings released: US$0.19 loss per share (vs US$0.33 loss in FY 2022)Full year 2023 results: US$0.19 loss per share (improved from US$0.33 loss in FY 2022). Revenue: US$88.1m (up 18% from FY 2022). Net loss: US$25.5m (loss narrowed 40% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 44% per year, which means it is performing significantly worse than earnings.
お知らせ • Mar 15Goodness Growth Holdings, Inc. to Report Q4, 2023 Results on Mar 28, 2024Goodness Growth Holdings, Inc. announced that they will report Q4, 2023 results at 4:00 PM, US Eastern Standard Time on Mar 28, 2024
分析記事 • Feb 01Investors Still Aren't Entirely Convinced By Goodness Growth Holdings, Inc.'s (CSE:GDNS) Revenues Despite 59% Price JumpGoodness Growth Holdings, Inc. ( CSE:GDNS ) shares have continued their recent momentum with a 59% gain in the last...
お知らせ • Dec 15Goodness Growth Holdings, Inc. Announces Departure of Michael Schroeder as General Counsel & Chief Compliance Officer Effective December 15, 2023Goodness Growth Holdings, Inc. announced that the Company’s General Counsel and Chief Compliance Officer, Michael Schroeder, will depart the Company effective December 15, 2023 to accept an external opportunity at Venture Medical, LLC, a national medical devices and wound care products distributor located in Missoula, Montana. The Company plans to retain external legal counsel on an interim basis to fulfill Mr. Schroeder’s former duties as General Counsel until a permanent successor can be identified, and will continue conducting its compliance procedures through a mix of existing internal and external resources.
Reported Earnings • Nov 17Third quarter 2023 earnings released: US$0.037 loss per share (vs US$0.066 loss in 3Q 2022)Third quarter 2023 results: US$0.037 loss per share (improved from US$0.066 loss in 3Q 2022). Revenue: US$24.7m (up 31% from 3Q 2022). Net loss: US$5.23m (loss narrowed 38% from 3Q 2022). Revenue is forecast to grow 16% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 44% per year, which means it is performing significantly worse than earnings.
お知らせ • Nov 03Goodness Growth Holdings, Inc. to Report Q3, 2023 Results on Nov 14, 2023Goodness Growth Holdings, Inc. announced that they will report Q3, 2023 results After-Market on Nov 14, 2023
お知らせ • Sep 28Goodness Growth Holdings, Inc. Announces CFO ChangesGoodness Growth Holdings, Inc. announced that Chief Financial Officer, John Heller, will depart the Company effective September 30 to accept a new external opportunity. Interim Chief Executive Officer Josh Rosen will assume the additional role of Interim Chief Financial Officer.
New Risk • Aug 16New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$15m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$15m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Negative equity (-US$7.9m). Earnings have declined by 17% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (CA$25.4m market cap, or US$18.9m).
Reported Earnings • Aug 15Second quarter 2023 earnings released: US$0.084 loss per share (vs US$0.048 loss in 2Q 2022)Second quarter 2023 results: US$0.084 loss per share (further deteriorated from US$0.048 loss in 2Q 2022). Revenue: US$20.2m (down 4.2% from 2Q 2022). Net loss: US$7.33m (loss widened 19% from 2Q 2022). Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings.
お知らせ • Aug 01Goodness Growth Holdings, Inc. to Report Q2, 2023 Results on Aug 14, 2023Goodness Growth Holdings, Inc. announced that they will report Q2, 2023 results After-Market on Aug 14, 2023
New Risk • Jul 22New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 11% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Negative equity (-US$2.1m). Earnings have declined by 19% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (11% increase in shares outstanding). Market cap is less than US$100m (CA$27.8m market cap, or US$21.1m).
Reported Earnings • May 17First quarter 2023 earnings released: US$0.066 loss per share (vs US$0.11 loss in 1Q 2022)First quarter 2023 results: US$0.066 loss per share (improved from US$0.11 loss in 1Q 2022). Revenue: US$19.1m (up 22% from 1Q 2022). Net loss: US$8.41m (loss narrowed 42% from 1Q 2022). Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
お知らせ • May 10Goodness Growth Holdings, Inc. to Report Q1, 2023 Results on May 15, 2023Goodness Growth Holdings, Inc. announced that they will report Q1, 2023 results at 4:00 PM, US Eastern Standard Time on May 15, 2023
お知らせ • Feb 15+ 1 more updateGoodness Growth Holdings, Inc. Announces Management ChangesGoodness Growth Holdings, Inc. announced that Company founder, Dr. Kyle Kingsley, will assume the role of Executive Chairman. Chief Administrative Officer Amber Shimpa has been promoted to the role of President of the Company.
Price Target Changed • Jan 13Price target decreased to CA$0.85Down from CA$1.00, the current price target is provided by 1 analyst. New target price is 270% above last closing price of CA$0.23. The company posted a net loss per share of US$0.27 last year.
お知らせ • Dec 10Goodness Growth Holdings, Inc. Announces Departure of Christian Gonzalez-Ocasio as Chief Operating OfficerGoodness Growth Holdings, Inc. announced the departure of Chief Operating Officer, Christian Gonzalez-Ocasio. The Company intends to engage Mr. Gonzalez as a consultant for an interim period to help ensure a smooth transition with the Company's leadership team. Mr. Gonzalez had been serving as Chief Operating Officer of the Company since November 2020. He previously served as Executive Vice President of Operations, supporting manufacturing and retail initiatives, beginning in October 2019. The Company does not plan to immediately seek a replacement for the Chief Operating Officer position. Responsibilities of the position will be filled by a mix of existing internal resources.
お知らせ • Dec 06Goodness Growth Holdings, Inc Appoints Josh Rosen to the Role of Interim PresidentGoodness Growth Holdings, Inc. announced that it has appointed Josh Rosen to the role of Interim President, effective immediately. Mr. Rosen has been serving as a director of the Company since August 2021. While he will continue to serve on the Company's board of directors, his position as Interim President will significantly expand his roles and responsibilities. Mr. Rosen's new roles and responsibilities will focus on driving operational efficiencies and adult-use preparedness in the Company's various operating markets to better align resources to capitalize on the growing adoption of adult-use regulations and managing the Company's key capital and strategic relationships. Goodness Growth's C-Suite of executives will begin reporting directly to Mr. Rosen, effective immediately. Dr. Kyle Kingsley will continue in his role as Chairman and Chief Executive Officer, with primary responsibilities focused on collaborating with Mr. Rosen on strategy, government relations and the Company's ongoing commitment to effective medical cannabis products. Mr. Rosen and Dr. Kingsley will both report directly to the Company's Board of Directors. Mr. Rosen also serves as Managing Partner at Bengal Capital, and was formerly Chief Executive Officer and Chairman of 4Front Ventures. At 4Front, Josh helped lead the transformation of a pioneering industry consulting firm into an operations-focused, multi-state operator, notably including the acquisition of Cannex Capital. Prior to 4Front, Josh gained private equity experience managing the investment portfolio for a large family office and worked extensively in the public markets as an equity analyst, primarily at the global investment bank, Credit Suisse.
お知らせ • Nov 11Goodness Growth Holdings, Inc. to Report Q3, 2022 Results on Nov 14, 2022Goodness Growth Holdings, Inc. announced that they will report Q3, 2022 results After-Market on Nov 14, 2022
お知らせ • Oct 15+ 1 more updateGoodness Growth Holdings, Inc., Annual General Meeting, Nov 18, 2022Goodness Growth Holdings, Inc., Annual General Meeting, Nov 18, 2022.
お知らせ • Aug 26Goodness Growth Holdings, Inc. Announces Launch of Boundary Waters Pre-Rolls in MinnesotaGoodness Growth Holdings, Inc. announced the launch of its Boundary Waters line of premium cannabis pre-rolls focused on sustainability and environmental preservation. Inspired by Minnesota's Boundary Waters Canoe Area Wilderness, which exists within Superior National Forest, Boundary Waters pre-rolls are hand-rolled from premium whole flower and are available in Sativa, Indica and hybrid strains, and can be purchased in five-roll and ten-roll packs. The Company plans to donate a portion of proceeds from the sale of Boundary Waters products to help keep the Boundary Waters clean and safe. Boundary Waters pre-rolls come in sustainable packaging, made from 57% plant-based materials. The packages are recyclable and made to decompose at an accelerated rate in landfills, if not recycled. The pre-rolls themselves are made with biodegradable paper inserts. Boundary Waters pre-rolls are made from premium whole flower material and are available at launch in six strains, including Candy Glue, Chem Fruit Funk, Critical Jack, OG Kush, White Wedding and Flap Jacks. Boundary Waters pre-rolls are currently only available in Minnesota at Green Goods dispensaries operated by the Company's Minnesota subsidiary. Subject to regulatory approvals, the Company plans to expand the Boundary Waters brand to include additional product offerings and other markets.
Reported Earnings • Aug 12Second quarter 2022 earnings released: US$0.048 loss per share (vs US$0.044 loss in 2Q 2021)Second quarter 2022 results: US$0.048 loss per share (down from US$0.044 loss in 2Q 2021). Revenue: US$21.1m (up 48% from 2Q 2021). Net loss: US$6.18m (loss widened 13% from 2Q 2021). Over the next year, revenue is forecast to grow 96%, compared to a 61% growth forecast for the industry in Canada. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
お知らせ • Aug 12Goodness Growth Holdings, Inc. Announces Unaudited and Condensed Impairment Results for the Quarter Ended June 30, 2022Goodness Growth Holdings, Inc. announced unaudited and condensed impairment results for the quarter ended June 30, 2022. for the quarter, the company reported Impairment of long-lived assets of $54,739,000.
お知らせ • Aug 02Goodness Growth Holdings, Inc. Launches Cannabis-Infused Gummies in MinnesotaGoodness Growth Holdings, Inc. announced the addition of cannabis-infused gummies to its Vireo brand in Minnesota, in accordance with Minnesota's new regulations effective Aug. 1 allowing certified medical cannabis patients in the state to purchase certain edible products containing cannabis. The addition of edibles, including gummies with cannabis, into Minnesota's medical cannabis program offers an additional and sought-after delivery method for patients. Vireo's gummies are designed to meet the needs of a variety of cannabis patients. At launch, the gummies are available in 10mg THC formulations and in Key Lime, Concord Grape, Hawaiian Pineapple and Oxnard Strawberry flavors. An additional formulation, with equal amounts of THC and CBD and in Alfonso Mango flavor, is expected to follow. Vireo gummies are available in all eight of the Company's Green Goods® dispensaries in Minnesota. The launch of Vireo gummies in Minnesota comes after the Company's launch of edible gummies and chews under the HiColor™ brand in Maryland in late 2021, where it has since expanded to include seasonal flavors and new formulations, and the expansion of HiColor™ brand to the New York market in June 2022.
お知らせ • Jun 24Goodness Growth Holdings Launches Hicolor™ Cannabis Chews in New YorkGoodness Growth Holdings, Inc. announced the launch of HiColor™ cannabis-infused chews in New York, which are now available through the Company's retail and wholesale channels in the New York market. The new line of cannabis-infused edibles is now available in five gourmet flavors and two formulations. HiColor™ chews were designed to meet the needs of a variety of cannabis consumers, with product offerings in 10 mg THC and 10:10 CBD:THC formulations. At launch, the chews are available to New York patients in Key Lime, Concord Grape, Hawaiian Pineapple, Oxnard Strawberry and Alfonso Mango flavors. The chews are vegan, gluten-free, Kosher, non-GMO and use only natural flavors. HiColor™ chews are currently available in all four of the Company's Vireo Health dispensaries in New York, as well as in select licensed dispensaries across the state with additional licensed dispensaries expected to add HiColor™ to their product assortment over the coming months. The New York launch of HiColor™ follows the brand's debut in Maryland in late 2021, where it continues to see great success and expanded flavor and formulation options, including seasonal flavors and a new formulation combining THC and CBN. Subject to regulatory approval, the Company plans to launch the HiColor™ brand in its Minnesota market later this year when the state's medical cannabis program expands to allow cannabis-infused edibles, expected to begin in August.
Reported Earnings • May 13First quarter 2022 earnings released: US$0.11 loss per share (vs US$0.059 loss in 1Q 2021)First quarter 2022 results: US$0.11 loss per share (down from US$0.059 loss in 1Q 2021). Revenue: US$15.6m (up 19% from 1Q 2021). Net loss: US$14.6m (loss widened 112% from 1Q 2021). Over the next year, revenue is forecast to grow 91%, compared to a 87% growth forecast for the industry in Canada. Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.
お知らせ • May 12Goodness Growth Holdings, Inc. Reports Consolidated Impairment of Long-Lived Assets for the Three Months Ended March 31, 2022Goodness Growth Holdings, Inc. reported consolidated impairment of long-lived assets for the three months ended March 31, 2022. Impairment of long-lived assets were USD 5,313,176.
